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Introduction 
11. Introduction 
Siddha system is one of the ancient systems, contemporaneous with those of 
the submerged lands, Egyptian, Mesopotamian, Chinese and German medicines. It is 
a traditional, tried, time tested and trusted Indian System of Medicine. The unique 
nature of this system is its continuous service to humanity for more than five thousand 
years in combating diseases and in maintaining physical, mental and moral health. 
The Siddha Pharmacopoeia contains, herbal, mineral and animal products 
including substances of disgusting character. However, plant drugs are its mainstay. 
The focus of Siddha medical practice is using herbal drugs first. 
Medicinal plants constitute a group, which are of great value for domestic use 
and for export. The use of various parts of several plants cure special ailments has 
been in vogue from ancient times in our indigenous medicines. Now, plants are the 
only source of a number of well established and important drugs. According to the 
data provided by Foundation for Revitalization of Local Health Traditions (FRLHT), 
Bangalore, of about 8000 plant species, the Siddha System utilizes 1121 plants, while 
Ayurveda 1769, Unani 751 and the Folk System exploits 4671 species. The data may 
not be very accurate, but provides an overview of the importance of plant in the global 
health strategies and the Medicare Programmes. 1
                                                        
Due to the population explosion and the spread of new diseases, the necessity 
to identify new herbs sustains the medical care. The WHO is actively encouraging 
countries to use herbal medicines which have been traditionally used for centuries. 
                                                                         
Although the use of traditional remedies is advantageous, it does suffer some 
limitations. The identification of herbal crude drugs, with their botanical name, 
distribution, occurrence and identification of adulterations, substitutions, purity and 
genuineness is very difficult. Exact botanical identity of a phyto drug is the 
prerequisite for all further studies on drugs. 
In crude drug markets, many a times some phytodrugs happen to be fake, 
adulterated or substituted ones. The reason is because of the demand in large 
T.ammi - Omam C.viscosa - Naikadugu
H.niger -Kurosaniomam seeds
2quantities or the non-availability due to over exploitations of plants from natural 
resources, or the cost or out of ignorance. 
About 75% of the Indian populations rely heavily on the use of herbal drugs 
for the treatment of diseases.2 Efficacy of any medicine depends upon the genuineness 
of the raw material, used for its preparation. 
One such drug is ‘Kurosaniomam’ (Hyoscyamus niger). In Gunapadam 
Mooligai Vaguppu it is indicated for many diseases, including Vatha diseases. One of 
the Vatha diseases affecting a large population is Azhal Keelvayu, which is a painful 
degenerative joint disease.   
When Vayu is in vitiated condition in the body and if diets which stimulate the 
‘Pitha’ are taken, Azhal Keelvayu occurs. In this disease the swelling of the joint 
increases day by day. As ‘Pitha’ increases, ‘Kapha’ in the joint decreases and hence 
dryness occurs. So during flexion of the joint crepitus is produced. Stiffness and 
restricted movements also occur.3
“Kurosaniomam” is a versatile herb having wide medicinal properties.6 It is 
an economically viable medicinal plant, having national priority, 5 well known for its 
alkaloids. Its narcotic properties help in Pain Management and hence I chose to study 
this drug for Azhal Keelvayu. 
However while trying to procure this drug it was realized that it is not easily 
available in the market. In South Indian Markets a seed resembling ‘Omam’ 
(Trachyspermum ammi, Family: Umbelliferae) is being sold as H.niger. In North 
Indian markets seeds of ‘Cleome viscosa’, Family Capparaceae (Naikadugu) is sold as 
H.niger. Even in Gunapadam, H.niger is classified under ‘Omam’, which does not 
clearly indicate its narcotic properties. It is one of the ingredients of many Siddha 
medicines. But instead of ‘Kurosaniomam’ some other drug is added to these 
preparations, due to ignorance. 
Thus authentication also became a part of this study. 
Part - 1 
A Study on Kurosaniomam for Azhal Keelvayu 
Aim & Objective 
32. Aim & Objective 
Aim: 
To assess the efficacy of ‘Kurosanioma Churanam’ in the management of 
‘Azhal Keelvayu’ . 
Objective: 
The objectives of this study are: 
 To collect and identify the authentic sample of ‘Kurosaniomam’ seeds 
 To find out the therapeutic dose 
 To evaluate the therapeutic efficacy in treating Azhal Keelvayu. 
The goal of Azhal Keelvayu therapy is to decrease pain and maintain (or) 
improve joint function. 
Kurosanioma Churanam was subjected to the following studies: 
 Pharmacognostic Studies 
 Phytochemical Analysis 
 Preliminary Bio-Chemical Analysis 
 Acute Toxicity Studies 
 Anti-Inflammatory and Analgesic Activities 
 Clinical Study 
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A Study on Kurosaniomam for Azhal Keelvayu 
Review of Literature 
Botanical Aspect 
83.2 Botanical Aspect 
Classification: 
4 
 Kingdom  - Plant kingdom  
 Class   - Dicotyledons 
 Subclass  - Gamopetalae 
 Series   - Bicarpellatae 
 Order   - Personales 
 Family  - Solanaceae 
 Genus   - Hyoscyamus
 Species  - Niger
Synonyms 17
 Common henbane 
 Fetid night shade 
 Insane root 
 Hog’s-bean 
 Jupiter’s bean 
 Hen bell 
 Symphonica 
 Cassilata 
 Cassilago 
 Desus  caballinus 
 Jusquiame 
Vernacular Names 
18
 Tamil  - Kurosaniomam 
 Malayalam - Puka-yila 
 Kannada - Khurasanin Vadakka 
 Sanskrit - Parasika, Khorasani Yamani 
 Telugu  - Pogaku Dhumra Pattram 
 English - Common Henbane 
 Arabic  - Bazrul-banj 
 Hindi  - Khurasani Ajvayan 
Habitat 
19
An herb of temperate Western Himalayas from Kashmir to Gharwal, 
distributed over Northern and Western Asia, Europe and North Africa. 
9Period of Occurrence  
Plant is found more or less throughout the year and flowering occurs from 
February to March. Seeds mature from April to May. 
Description  
An erect  coarse viscid herb, stem branched and slightly hairy; radical leaves 
spreading, stalked, oblong ovate, coarsely sinuate, toothed;  leaves small, sessile, 
ovate,irregularly pinnatifid passing into bracts; flowers sub-sessile, yellowish green 
arranged on simple unilateral, recurved, leafy terminal spikes; calyx tube ovoid, limb-
funnel shaped, slightly unequal reticulate; stamens protruding, exerted and dishiscing 
longitudinally ; ovary 2 celled, style longer than stamens ; capsule 1.3 cm in diameter, 
enclosed in a globose tube of enlarged calyx, lower part membranous, tip hard and 
rigid opening transversely along the constriction between the two portions; fruits 
small 2-celled, containing numerous seeds. 
The fresh herb has a strong unpleasant odour and a slightly acrid taste, which 
nearly disappears on drying. 
Parts Used 
Leaves, seeds, branches and flowering tops. 
Method and Time of Collection 
Generally, biennials are preferred for the purpose of medicine. For seed 
collection, the plants are left in the field until the fruits ripen and pulled from the roots 
before the fruit dehisces. The fruits are then spread in the sun for 2 or 3 days and 
racked with sticks when the fruits are open. A single plant yields approximately 
10,000 seeds. 
Preservation and Storage 
Seeds are garbled, sieved and stored in dry bottles and kept in cool place and 
protected from moisture. Generally, the seeds retain their medicinal efficiency up to 5 
years. 
10
Method of Processing (Unani) 
As Kurosaniomam has toxic action it is used in de-toxicated form for 
medicinal purposes, by adding vinegar to the drug and soak it for 3 consecutive 
nights. The level of vinegar should be 4 times above the level of drug. After soaking 
the seeds are dried and used.  
Dose   – 200 to 500 mg   
Correctives  – Pure honey. 
 Composition of Hyoscyamus Leaves and Seeds 20
The most important constituent of Hyosyamus is the alkaloid hyocyamia or 
hyoscyamine obtained from both seeds and leaves. 
The chief constituent of the seeds is about 0.5 – 0.6% of alkaloid hyoscyamine 
with a small proportion of hyoscine. The seeds also contain about 20% of fixed oil. 7
Other constituents of H.niger leaves are a glucosidal bitter principle called 
hyosctricin, choline, mucilage, albumin, calcium oxalate and potassium nitrate. By 
destructive distillation, the leaves yield very poisonous empyreumatic oil. 17
Analytical Data 8
Identity, purity, strength and assay 
Foreign organic matter                                Nil 
Purity 100% 
Identity 100% 
Physico – chemical constant (%) 
Total ash 8.29 
Acid insoluble ash 4.07 
Water soluble ash 0.47 
Moisture content 6.30 
Successive extractive values (%) 
Alcohol  10.40 
Ether 0.88 
Petroleum ether 1.72 
Chloroform 1.72 
Distilled water  7.50  
11
 Medicinal Properties and Uses 
20
Seeds: 
The seeds are the only part of the plant used in native practice in India.11
Experiments have shown that the seeds not only possess all the properties of the plant, 
but have ten times the strength of the leaves. Given as a substitute for opium where 
the administration of opium is objectionable, as it does not cause constipation and 
sickness like it. Milder deliriant than belladonna but more hypnotic, quicker acting.
H.niger has anodyne, narcotic, mydriatic, astringent, carminative, digestive, 
anthelmintic, stomachic and intoxicating properties. It has parasympatholytic, 
anticholinergic and central nervous system depressant effects.          
The drug contains the therapeutic actions of its 2 alkaloids hyoscyamine and 
hyoscine. Because of the presence of hyoscyamine it checks secretion and relaxes 
spasms of involuntary muscles, while through the narcotic effects of hyoscine it 
lessens pain and exercises a slight somnifacient action. Like belladonna, produces 
dilation of pupil, somnolency, a parched condition of the tongue and mouth and in-
sufficient doses causes delirium. 
 The general action is on the secretions and nervous system. 
 The influence of H.niger on cerebrum and motor centres is greater while its 
stimulant action on the sympathetic is less. 
 The fume of the dried herb stalks and seeds burned quickly heals swellings, 
chilblains in the hands or feet by holding them in the fume thereof. 
 As an external application it may be employed in various neuralgic and other 
painful and irritable affections. 
 In India, H.niger seeds are prescribed by the Mohammedan doctors, to sooth the 
mind, procure sleep, and keep the bowels gently open in cases of melancholia and 
mania. 
 Directly stimulates the heart, but after moderate doses the action of henbane 
results in a sedative effect. Small doses of henbane are sedative and tonic to the 
heart. Large doses excite it, and excessive doses depress it. 
12
 H.niger is a valuable remedy in cardiac and pulmonary asthma; in excited cardiac 
action from valvular disease. 
 Produce relaxation of the voluntary muscles and of the intestine and bladder. 
 An anodyne in renal colic and numerous other affections. 
 Useful remedy in painful spasmodic affections of the involuntary muscles of the 
uterus, bladder and urethra, it also relieves pain in cystitis. 
 Used to relieve the gripping caused by drastic purgatives especially those 
containing aloes and colocynth. It acts without diminishing the peristalsis. 
 Useful in hypochondriasis and emotional epilepsy.  
 It is used to allay nervous irritation in various forms of hysteria or irritable tough. 
Given as an antispasmodic in asthma. 
 In small repeated doses, H.niger has been found to have a tranquillizing effect 
upon persons affected by severe nervous irritability, producing a tendency to sleep, 
not followed by the disorder of the digestive organs and headache, which too 
frequently result from the administration of repeated doses of opium. 
 The oil of the seed is helpful for deafness, noise and worms in the ears, being 
dropped in. 
 The decotion of the herb or seed or both kills lice in man. 
 Smoke of seeds is used as domestic remedy for toothache. 
 The seeds in wine are applied to gouty enlargements, inflamed breasts and swelled 
testicles. 22
 The mixture of the powdered seeds, used as a pessary in painful affections of the 
uterus. 
 The herb was used in magic and diabolism. 17
 Anodyne necklaces were made from the root and were hung about the necks of 
children as charms to prevent fits and to cause easy teething.  
 Small quantities of H.niger seeds added to the forage of the cattle to fatten them.  
13
Leaves: 17
Leaves of H.niger are official in all Pharmacopoeias. 
 A sedative application for external use is prepared by macerating leaves in 
alcohol, mixing the strong tincture with olive oil and heating in a waterbath 
until the alcohol is dissipated. 25
 A liniment prepared from the leaves when applied to the skin relieving 
obstinate rheumatic pains. 
 The fresh leaves crushed and applied as a poultice or fomentation will relieve 
local pains of gout and neuralgia. As a palliative it applied to allay pain in 
cancerous ulcers, irritable sores and swellings. 
 The leaves cool all hot inflammations in the eye. 
 Applied with vinegar to the forehead and temples, relieves headache in fevers. 
 The tincture or juice prepared from the fresh leaves and tops being given in 
mixtures as an antispasmodic in asthma. 
 Combined with sliver nitrate, it is useful in the treatment of gastric ulcer and 
chronic catarrh. 
 A watery solution of the extract applied to the eyes, is dilating the pupil, and 
leaves no injurious effect afterwards. 
 The extract in the form of suppositories alleviate the pain of haemorrhoids. 
 Dosages  
o Powdered leaves 2-10 grain  
o Juice B.P ½ to 1 drachm 
o Fluid extract 2-10 drops, tincture B.P and U.S.P – ½ to 1 drachm. 
o Solid extract 2-8 grains 
o Hyoscyamine 1/8 to 1 grain 
Medicinal Uses of Alkaloids Obtained From H.niger 
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 Hyoscyamine is intermediate in its action between atropine and hyoscine. It is 
a weaker sedative and hypnotic than hyoscine. Peripherally it acts powerfully. 
14
 Hyoscyamine is injected hypodermically in epilepsy, obstinate insomnia, 
hallucinations, in tremors of paralysis agitans or in mercurial tremors, to 
relieve pain and disordered coordination as in loco-motor ataxia. 
 Hyoscyamine sulphate is administered hypodermically or given in pills for 
mental excitement and insomnia. Doses of 0.6 mg are recommended in sea 
sickness, one every hour if required. 
 Hyoscine is a very powerful anodyne, hypnotic and sedative. 
 Hyoscine hydro bromide 0.5 mg IM has been used in pre-anaesthetic 
medication. 
 A preparation for transdermal administration of Hyoscine with rate controlled 
sustained delivery over 72 hours used in the prophylaxis of motion sickness 
 In obstetrics, hyoscine has been combined with Pethidine to produce ‘twilight 
sleep’ 
 Hyoscine had earned a reputation as a ‘lie detector’ during worldwar II. Its 
amnestic and depressant action was believed to put the subject ‘off guard’ in 
the face of sustained interrogation and sleep deprivation, so that he came out 
with the truth. 24
 Hyoscine butyl bromide – adult dose 10mg – 4 times daily by oral route or as 
IM (or) IV injection in intestinal, biliary and renal colic. 
 A clinical comparison has been made by Vollmer, of value of these alkaloids 
in the treatment of Parkinson’s Syndrome. 32
Toxicity Produced By H.niger Seeds 
All plant parts contain tropane alkaloids (hyoscyamine, hyoscine and atropine) 
and toxic to humans and animals when ingested in large doses. Neither drying nor 
boiling destroys the active principle.17
Hyoscyamus niger has anticholinergic property.23 In higher doses, it produces 
anticholinergic syndrome characterised as, 
“Hot as fire, red as beet, dry as a bone 
Blind as a bat and mad as a hen” 
15
CNS Effects Produced By Higher Doses of H.niger
The CNS effects are nausea, restlessness, anxiety, vomiting, hallucination, 
mania and convulsions.  
With very high dose, CNS excitation is followed by severe depression, coma 
and paralysis of medullary centres. It rises body temperature up to 1090F which is 
common in children and infants. Respiration is initially rapid, subsequently there may 
be respiratory arrest. B.P may rise or fall. 
Peripheral Effects 
Mydriasis, xerotomia, dysphagia, excessive thirst, difficulty in micturation, 
diminished intestinal peristalisis, palpitation, tachycardia, cardiac tacharrhythmias, 
peripheral cutaneous vasodilatation, skin rash etc.
   
Antidotes
17
Honey, honeyed water, goat’s milk, fennel seeds, nettle seeds, mustard, radish, 
pine kernels with sweet wine, onions or garlic with wine. 
Studies on Kurosaniomam 
1. 2002 – 04 – 2427 (Ma. C.Y., Liu W.K., Che C.T)., Department of Chemistry 
Hong Kong University of Science and Technology. Lignanamides and non 
alkaloidal components of H.niger seeds, Journal of natural products, Vol 65 
(2): page 206 – 209, 2002. 
2. 2006 – 04 – 1947 Page no 517, MAPA; Hyosgerin, a new optically active 
coumarinolignan isolated from the seeds of H.niger.
3. 2005 – 06 – 3108 Page no 760 MAPA; The complete amino acid sequences of 
2Fe – 2S Ferredoxin from Atropa belladonna and H.niger was determined by 
automated Edman degradation of the entire S – Carboxymethyl cysteinyl 
proteins and of the peptides obtained by enzymatic digestion.  
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4. PubMed: Some activities of 7 vegetable extracts including H.niger & 
A..belladonna, & an association of them given by oral route were tested on 
C.N.S. of mouse. H.niger proved to be active in one of the tests performed. 
[Article in Italian] Della Loggia 1981 (Pharmacodynamics) 
5. PubMed: [Thiophosphoric acid derivatives of ethylamine, DL-methionine, and 
L-proline ethyl esters. IV. Biological activities in seeds of H.niger] Klee 1962 
(Pharmacodynamics) 
6. PubMed: Three withanolide class steroids were isolated from the seeds of 
H.niger. Two of them were identified as daturalactone-4(1) and Nic-3 (which 
is now named hyoscyamilactol. Ma 1999. 
7. PubMed: The seeds of A. belladonna, Datura fastuosa, D.stramonium &
H.niger were investigated for isolation & anti-microbial activity of non-
alkaloidal constituents. The compounds were separated by coloumn 
chromatography & identified by IR & UV spectral studies. Khan 1992 
Part - 1 
A Study on Kurosaniomam for Azhal Keelvayu 
Materials, Methods and Results 
Preparation of the Drug 
Kurosanioma Churanam
Kurosaniomam Seeds
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4. Materials, Methods and Results 
4.1 Preparation of the drug 
The seeds of Kurosaniomam were taken for study. The seeds of 
Kurosaniomam (H.niger) were purchased from Gautham Global Seed Merchants; 
Dehradun. The drug was identified and confirmed by the botanist. 
Initially the seeds are garbled and sieved, then made into powder. The powder 
is coarse, due to the oil content. Then it was purified by Pittavial method. 
Route of administration  - Enteral route 
Dose                               - 300mg 
Vehicle             - Water                                          
Part - 1 
A Study on Kurosaniomam for Azhal Keelvayu 
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4.2 Pharmacognostic Study 
      
Market samples of the drug ‘Kurosaniomam’ was procured from ‘Gautham 
Global Seed Merchants’ Dehradun under the name H.niger and identified by  
Dr.Sasikala Ethirajulu, Research Officer (Pharmacognosy), Central Research Institute 
For Siddha, Arumbakkam, Chennai-106, based on the macroscopic characters of the 
drug. 
The dried seeds procured from the drug dealer were revived by boiling them in 
teepal-water mixture. This procedure enabled the tissues of the specimens to regain 
their original form and dimensions. They were sectioned and stained with safranin.  
Macroscopic:  
Seeds are (small 0.8x1 – 1x1.5mm in size), laterally compressed, 
scrobiculate,exarillate and albuminous. They are dark brown in colour with finely 
reticulate seed coat having a pungent tobacco like smell and a characteristic bitter 
taste. Weight of one hundred seeds varies from 4to7gm.  
Microscopic: 
The seeds in longitudinal section shows a circular outline and is all-round 
covered by a 0.14-0.21 mm thick seed coat which reveals a simple histological 
structure .The outermost envelope of seed i.e., the epidermis is composed of a single 
row of thick walled radially elongated cells, the outer walls of which are thin, but 
lateral and interior ones are very much thickened. They show a close affinity to 
macrosclereids. The second layer which made up of comparative small tangentially 
extended cells which are closely applied to one another. Vascular bundles are short 
and generally not reaching the endosperm. Endosperm is cellular polyhedral, 
parenchymatous, thin walled containing aleurone grains and oil globules. 
Parenchymatous cells of cotyledons are also thin walled. 
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 Study of the Powdered Drug: 
The seed powder is characterized by blackish brown colour, pungent odour, 
and a bitter taste. The seed powder when cleared with 75% chloral hydrate under the 
microscope shows fragments of columnar palisade cells, xylem elements with usually 
spiral thickenings, some thin-walled parenchyma cells and abundance of 
small,roundish oil globules and aleurone grains. 
      
Reaction of Chemicals with Crude Powdered Drug - Table -1 
 CHEMICALS TREATED OBSERVATION         
Treated with sulphuric acid (66%) solution         Blackish brown colour 
Treated with sodium hydroxide  (5%) solution         Dull Yellow colour 
Treated with ferric chloride (5%) Solution Yellow colour 
Treated with sodium hydroxide  (5%) solution and 
heated 
Yellow colour 
Fluorescence Analysis of the Powdered Drug - Table -2 
Treatment ORDINARY LIGHT                    UV LIGHT (254nm) 
Acetone yellow                                         light green 
Benzene greenish yellow                          pale green 
Chloroform dull light brown                          pale green 
Ethanol      greenish yellow                         yellowish green 
Petroleum ether   light greenish yellow                 pale  yellowish green 
Ether       light green                               light greenish yellow 
Methanol    yellowish green                       whitish green 
Distilled water        colourless  pale green 
Powder as such  blackish brown brown black 
Part - 1 
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4.3 Bio-Chemical Analysis:  
(Dept of Bio Chemistry, GSMC, Chennai) 
Preparation of Extract: 
5 gm of Kurosanioma Churanam is weighed accurately and placed in 250 ml 
clean beaker and 50 ml of distilled water is added. Then it is boiled for about 10 
minutes. After which it is cooled and filtered in a 100 ml volumetric flask and made 
up to 100 ml with distilled water. 
Test for acid radicals - oxalate: 
Experiment Observation Inference 
5 drops of clear extract is added with 2ml of 
dilute sulphuric acid and slightly warmed. To 
this, 1 ml of dilute potassium permanganate 
solution is added. 
Potassium 
permanganate 
solution is 
decolourised  
Presence of 
oxalate.  
Reveals the presence of Oxalates. 
Part - 1 
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4.4 Preliminary Phytochemical Study 
This study was done at Vel's College of Pharmacy, Velan Nagar, Pallavaram 
Chennai - 600 117, Tamil Nadu, India.  
The following tests were done: 
 For Alkaloids -   Mayer’s test, Dragendroff’s test.
 For Carbohydrates and Glycosides - Molisch’s test and Borntrager’s test. 
 For Cardiac Glycosides - Legal’s test and Keller-killiani test. 
 For Sugars - Fehling’s test and Benedict’s test. 
 For Steroids - Liebermann’s Burchard test and Salkowski test. 
 For Tannins. 
 For Proteins - Millon’s reagent, Biuret test, Ninhydrin test, Xanthoprotein test.  
 For Terpenoids - Noller’s test. 
 Tests for Flavonoids - Shinoda test. 
 For Anthocyanins. 
 For Quinones. 
The results are given in table – 3. 
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Preliminary Phytochemical Study of Kurosanioma Churanam - Table – 3 
TESTED FOR RESULT 
Carbohydrates and Glycosides 
 Molish’s Test 
 Legal’s Test 
 Borntrager’s Test 
Absent 
Alkaloids 
 Mayer’s reagent   
 Dragendroff’s reagent 
 Hager’s reagent 
 Wagner’s reagent 
Present 
Phytosterol 
 Libermann Burchard Test 
Present 
Fixed Oils 
 Spot Test 
Present 
Gums and Mucilages Absent 
Saponins Absent 
Proteins and Free Amino Acids 
 Million’s reagent 
 Ninhydrin reagent 
 Biuret test 
Present 
Phenolic Compounds and Tannins Present 
Flavonoids 
 Shinoda’s Test 
Present 
Triterpenoids Present 
Steroids Present 
Part - 1 
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4.5 Pharmacological Studies 
Acute Toxicity Study of Kurosanioma Churanam  
Animals 
Albino mice were used in this study; they were maintained under standard 
animal house conditions, fed on commercial feed pellet, and water ad libitum. All 
experimental protocols were approved by IAEC.  
Acute toxicity 
Healthy albino mice of either sex, weighing around 22-28 g, and overnight- 
fasted, were used for study. Food was withdrawn during the study, however free 
access to water was provided. The weighed animals were randomly assigned to seven 
groups of six animals each (n=6), and were administered the kurosanioma churanam 
orally, in the increasing doses 50, 100, 500, 1000, 2000 and 4000 mg/kg, (Table-4). 
Acute toxicity-Results of Kurosanioma Churanam 
Death was recorded during the treatment period in 1500mg/kg dose given 
groups orally. Hence it can be concluded that a test substance is practically toxic after 
an acute exposure to 1500mg/kg dose.  
Incremental dose finding experiment and its signs of toxicity (Table – 4) 
N
o 
Treat
ment 
Dose 
mg/ml/kg 
1 2 3 4 5 6 7 8 9 
1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
1. I 100 + + - + + + - + - - - - - - - + - - - - 
2 II 250 + + - + + + - + - - - - - - - + - - - - 
3 III 500 + + - + + + - + - - - - - - - + - - - - 
4 IV 1000 + + - + + + - + - - - - - + - + - - + + 
5 V 1500 + + - + + + - + - - - - - + - + - + 
+
+ 
3
+ 
6 VI 2000 + + + + + + - + + + - - - + - + + + 
+
+ 
4
+ 
7 VII 4000 + + + + + + - + + + -- - - + + + + + 
+
+ 
6
+ 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming  5. Gripping  6. Touch Response 7. Increased 
Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 11. Catatonia 12. Muscle relaxant 13. 
Hypnosis 14. Analgesia 15.Lacrimation 16. Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. 
Number of Deaths (Mortality) 
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Anti-inflammatory and Analgesic Studies 
Materials and Methods 
Animals 
Male Wister rats weighing approximately 150 g and male albino mice 
weighing approximately 30 g were chosen for anti-inflammatory and analgesic 
studies, respectively. They were kept in polypropylene cages in groups of six animals 
each, fed with standard rat feed and given water ad libitum.  
Anti-inflammatory study 
Formalin induced oedema in rats: 
In this method 0.1 ml. of 2% of Formalin was injected in the plantar 
aponeurosis of the right hind paw for all rats. Overnight – fasted Wistar rats were 
randomly assigned to 3 groups.  Each group consisted of six animals. The first group 
of rats was treated with vehicle alone. Second group was treated with the standard 
drug, diclofenac at the dose rate of 45mg/ kg body weight. Other two groups were 
treated with Kurosanioma churanam suspended in 2% CMC vehicle, administered 
orally at the dose rate of 150 and 300mg/kg body weight, respectively. Paw volume 
was measured before and two hours after Formalin injection by Plethysmograph. 
Percentage of activity was calculated by the formula (1- T/C) 100, where T and C are 
the mean values of the drug treated and the control group, respectively. (Ref. Table – 
5). 
Anti-Inflammatory Study Results 
The development of oedema is bi-phasic, the first phase is attributed to the 
release of histamine, 5-HT and kinins, while, and the second phase is related to the 
release of prostaglandins. Administration of Kurosanioma churanam and diclofenac at 
45mg/ kg at the doses employed in Formalin induced inflammation in rats showed 
significant inhibition of paw edema, (p<0.01). Results showed that administration of 
Kurosanioma churanam at a dose of 150mg/kg and 300mg/kg exhibited moderately 
significant anti-inflammatory effect. 
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Effect of Kurosanioma Churanam on Formalin - induced edema in hind paw of 
rats (Table 5) 
S.no Treatment Dose (mg/kg) Mean increase in paw 
volume (Mean±SEM)
Percentage inhibition 
1 Control 5ml/kg 0.42±0.56 ---- 
2 Diclofenac sodium 25mg/kg 0.26±0.08** 38.09 
3 K.O.C. 150mg/kg 0.32±0.64* 23.80 
4 K.O.C. 300mg/kg 0.29±0.71** 30.95 
*P<0.05; **P<0.01 compared to control. 
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Analgesic Study 
The present study was undertaken to study its analgesic eftect in mice. 
Analgesic activiy was assessed by the method of Eddy’s hot plate following oral (150 
and 300 mg/kg) administration of the Kurosanioma churanam in groups of 6 mice 
each. The Kurosanioma churanam was effective by oral route as tested by this 
method. The duration as well as intensity of analgesia was dose dependent. Analgesic 
effect lasted for a period of 2 hrs was found to possess significant (P < 0.01) analgesic 
activity by Eddy’s hot plate method. (Table-6).   
Analgesic Study Results 
Results of the current study demonstrated that treatment with Kurosanioma 
churanam at moderate dose showed significant analgesic effect. The analgesic effect 
of the drug as observed by Eddy’s hot plate method was dose related. The analgesic 
effect of this drug when used may be of great value in relief of pain.   
Effect of Kurosanioma churanam on reaction time in albino mice (Table 6) 
Reaction time after drug treatment .Treatment Dose 
mg/Kg
No of 
animals
Reaction 
time in sec. 
before drug 30min 60min 120min 
K.O.C 150 6 2.16 ± 
0.307 
2.33±0.16ns 3.48±0.43* 3.8 
±0.39* 
K.O.C 300 6 2.25 ± 
0.390 
2.99 ± 
0.30* 
4.4 ± 
0.61** 
5.2 
±0.28** 
Pentazocin 5 6 2.29 ± 
0.301 
 6.12± 
0.42** 
10.2 ± 1.2* 10.6 ± 
1.8** 
Control --- 6 2.30±0.335 2.41±0.96 2.21±0.62 2.86±0.88
*P<0.05; **P<0.01 compared to control. 
Part - 1 
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4.6 Clinical Study 
This was an open non comparative clinical trial 
The clinical study was carried out in Gunapadam Post Graduate Out Patient 
Department, Arignar Anna Hospital, Chennai-106. 
Selection of Patients 
60 patients were selected in both sexes. The selection of patients was based on the 
following inclusion and exclusion criteria. 
Inclusion Criteria 
 Age - 40 and above  
 Sex – both male and female  
 Pain-knee joint only  
 Swelling 
 Crepitus  
 Restricted movements 
Exclusion Criteria  
 Fever   
 Pain in other joints other than knee  
 Effusion  
 Other types of arthritis. 
Withdrawal Criteria  
 Irregular treatment  
 Patients who followed dual treatment 
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Treatment Schedule  
 ‘Kurosanioma churanam’-300mg, two times a day, after food. 
 Vehicle-water  
 Route of administration-enteral route  
 Duration -6 weeks 
    
Study Procedures  
60 patients were selected for clinical trial on the basis of inclusion criteria. For 
all the cases full clinical data was recorded and they were diagnosed on the basis of 
Siddha principles and Modern parameters.  
The patients were followed up for 6 weeks and the evaluation was recorded at 
the end of each week and a complete clinical and the following lab investigations 
were done at the first week and at the end of the 6th week. 
 Urine routine  
 Blood    
o TC,DC, ESR 
o Sugar(R),  Urea, Cholesterol 
 X- ray knee joint  
Medical Advice and Diet 
  
The patients were advised,  
 To take easily digestible and nutritive food  
 To avoid food aggravating VATHA, eg: tubers, dhal etc  
 To avoid exposure to cold and damp environment  
 To perform mild exercises, those strengthen the quadriceps muscles.  
 To avoid non veg. diet, smoking and alcohol. To take rest, but avoid prolonged 
immobilization which leads to joint stiffness and further incapacitate to walk.  
 To perform yoga.  
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Bio-Statistical Analysis: 
The statistical analysis of the clinical observations was analyzed with the help of a 
statistician where the following two tests were used to find the significance of the 
results. 
T – Test: The t- test is a statistical test that helps to show if there is a real difference 
between different treatments / phases of treatments being tested in a controlled clinical 
trial. 
Chi square test:  A statistical test used to determine the probability of obtaining the 
observed results by chance, under a specific hypothesis. 
X-ray
TC Sug-R Chl Urea
cells/cu.mm P L E 1/2hr 1hr mg/dl mg/dl mg/dl
Before 10000 60 34 6 4 10 130 205 29 Nil Nil Few Epicells
After 9800 55 40 5 8 13 128 186 24 Nil Nil Few Epicells
Before 9400 55 41 4 2 3 80 171 18 Nil Nil Few Epicells
After 9800 60 34 6 10 14 113 188 19 Nil Nil Occ Puscells
Before 9200 58 38 4 10 15 113 182 29 Nil Nil Few Epicells
After 9400 54 42 4 8 15 92 173 23 Nil Nil Few Epicells
Before 10200 63 32 5 5 9 172 160 27 Nil Nil Few Epicells
After 9200 60 34 6 5 10 162 170 29 Nil Nil Occ Puscells
Before 9600 65 30 5 12 18 138 179 29 Nil Nil Few Epicells
After 9400 65 32 3 6 13 142 183 26 Nil Nil Few Epicells
Before 9800 59 40 1 7 10 130 145 20 Nil Nil Few Epicells
After 9800 69 30 1 9 12 100 143 20 Nil Nil Few Epicells
Before 9800 60 34 6 15 34 113 205 19 Nil Nil Few Epicells
After 9600 62 33 5 12 20 100 200 18 Nil Nil Few Epicells
Before 9200 58 36 6 12 20 188 193 23 Nil Nil Occ Puscells
After 9400 62 34 4 10 15 200 180 20 Nil ++ Few Epicells
Before 9700 58 36 6 12 20 170 210 25 Nil +++ Few Epicells
After 9200 58 36 6 10 20 180 193 23 Nil ++ Occ Puscells
Before 10200 64 31 6 12 20 132 150 16 Nil Nil Few Epicells
After 9800 58 38 4 10 18 140 132 12 Nil Nil Few Epicells
Before 10200 58 36 6 5 12 289 182 24 Nil ++ Occ Puscells
After 9800 56 41 3 8 12 232 180 24 Nil + Few Epicells
Before 10100 62 28 10 12 20 135 192 18 Nil Nil Few Epicells
After 9800 56 98 6 7 15 128 200 17 Nil Nil Few Epicells
Before 9400 53 30 7 12 25 125 179 23 Nil Nil Occ Puscells
After 8600 60 36 4 5 8 120 162 19 Nil Nil Few Epicells
Before 9800 59 36 5 24 50 98 210 19 Nil Nil Few Epicells
After 9600 56 40 4 12 20 102 192 20 Nil Nil Few Epicells
Before 9800 60 34 6 32 60 118 180 19 Nil Nil Few Epicells
After 9400 63 32 5 15 22 110 172 19 Nil Nil Few Epicells
Before 9200 57 38 5 20 44 114 155 23 Nil Nil Few Epicells
After 9400 58 39 3 13 18 120 162 18 Nil Nil Few Epicells
Moderate
Duration Urine
Sex
Occup-
ation From 
F
House 
wife
20/06/07 13/07/07
S.
No
OP.
No
Name Age
10 1623 Kasthuri 55
Pain, 
Crepitus, 
swelling, RM
7 3715 Sikkandhar Beevi 50 F
House 
wife
18/06/07 01/08/07
Pain, 
swelling, RM
8 4341 Vasantha 57 F
House 
wife
19/06/07 23/07/07
Pain, 
Crepitus, RM
9 4320 Gunavathi 52 F
House 
wife
19/06/07 23/07/07
Pain, 
Crepitus, RM
11 4517 Maheswari 57 F
Veg 
Vendor
20/06/07 19/07/07
Pain, 
swelling, RM
1 1615 Thara 50 F
House 
wife
11/06/07 23/07/07
Pain, 
Crepitus, RM
2 1649 Anand 41 M Tailor 11/06/07 12/07/07
Pain, 
Crepitus, RM
3 1547 Gopi 50 M Vendor 11/06/07 20/07/07
Pain, 
Crepitus, 
swelling, RM
4 1540 Ansar 55 M Attender 11/06/07 10/07/07
Pain, 
Crepitus, 
swelling, RM
5 1600 Kaleel 45 M Peon 11/06/07 20/07/07
Pain, 
swelling, RM
Pain, 
Crepitus, 
swelling, RM
20/07/076 1863 Srinivasan 63 M Labourer 12/06/07
12 5914 Imam 46 M
Shop 
keeper
25/06/07 10/08/07
Pain, 
Crepitus, RM
13 6060 Bhavani 43 F
House 
wife
25/06/07 23/07/07
Pain, 
swelling, RM
14 6195 Jayalakshmi 63 F
House 
wife
25/06/07 07/08/07
Pain, 
swelling, RM
15 6839 Noor Jahan 47 F
House 
wife
27/06/07 07/08/07
Pain, 
Crepitus, 
swelling, RM
16 6837 Shanu 40 M Vendor 27/06/07 07/08/07
Pain, 
Crepitus, 
swelling, RM
Blood
To
Compliants Stage ResultsDC - % ESR - mm
Alb Sug Dep KJ
Osteophytes
Narrowing of Jt. Space
Narrowing of jt. Space
Osteophytes
Narrowing of Jt. Space
Osteophytes
Narrowing of Jt. Space
Narrowing of jt. Space
Soft tissue swelling
Osteophytes
Narrowing of jt. Space
Osteophytes
Narrowing of Jt. Space
Osteophytes
Narrowing of Jt. Space
Osteophytes
Osteophytes
Narrowing of Jt. Space
Soft tissue swelling
Narrowing of jt. Space
Narrowing of jt. Space
Osteophytes
Osteophytes
Osteophytes
Good
Moderate
Moderate
Moderate
Good
Good
Good
Good
Good
Moderate
Good
Good
Good
Good
Good
X-ray
TC Sug-R Chl Urea
cells/cu.mm P L E 1/2hr 1hr mg/dl mg/dl mg/dl
Duration Urine
Sex
Occup-
ation From 
S.
No
OP.
No
Name Age
Blood
To
Compliants Stage ResultsDC - % ESR - mm
Alb Sug Dep KJ
Before 9400 57 39 4 5 14 89 208 28 Nil Nil Occ Puscells
After 9800 54 42 4 8 12 98 202 22 Nil Nil Occ Puscells
Before 9200 55 41 4 11 20 238 210 27 Nil ++ Few Epicells
After 9220 60 36 4 12 18 192 208 22 Nil ++ Few Epicells
Before 6100 81 13 6 9 20 97 188 18 Nil Nil Nil
After 8000 70 27 3 4 10 92 172 20 Nil Nil Few Epicells
Before 10000 63 32 5 5 12 132 159 28 Nil Nil Occ Puscells
After 9400 58 37 5 7 15 128 163 24 Nil Nil Few Epicells
Before 8000 55 38 7 5 12 101 125 21 Nil Nil Occ Puscells
After 8400 67 30 3 7 12 98 132 18 Nil Nil Few Epicells
Before 10200 63 32 5 12 20 93 175 18 Nil Nil Occ Puscells
After 9600 62 34 4 8 16 92 56 18 Nil Nil Few Epicells
Before 5400 52 45 3 8 15 104 193 24 Nil Nil Nil
After 7600 65 30 5 4 8 118 190 20 Nil Nil Few Epicells
Before 10700 65 31 4 20 36 109 183 23 + Nil Occ Puscells
After 9800 62 33 5 14 26 112 192 22 Nil Nil Few Epicells
Before 10600 63 32 5 25 52 138 182 18 Nil Nil Few Epicells
After 9600 55 41 4 21 32 123 188 20 Nil Nil Few Epicells
Before 8700 53 39 8 20 44 88 182 18 Nil Nil Few Epicells
After 9200 58 37 5 18 20 98 188 18 Nil Nil Few Epicells
Before 10200 68 26 6 20 38 105 180 22 Nil Nil Few Epicells
After 9400 52 43 5 16 22 98 172 20 Nil Nil Few Epicells
Before 9800 57 38 5 25 26 163 208 21 Nil Nil Few Epicells
After 9800 62 34 4 14 28 152 192 20 Nil Nil Few Epicells
Before 9400 50 45 5 12 28 180 182 22 + + Occ Puscells
After 9600 54 40 6 10 18 166 178 18 Nil + Few Epicells
Before 9800 52 42 6 11 12 109 165 20 Nil Nil Few Epicells
After 9600 66 30 4 5 13 98 153 80 Nil Nil Occ Puscells
Before 9400 58 36 6 5 12 102 162 18 Nil Nil Few Epicells
After 8900 54 42 4 4 10 100 158 20 Nil Nil Few Epicells
Before 10200 63 33 4 11 20 168 165 28 Nil Nil Few Epicells
After 10000 65 61 4 12 20 172 164 24 Nil Nil Few Epicells
17 6828 Shanmugam 42 M Tailor 27/06/07 01/08/07
Pain, 
swelling, RM
18 7265 Ettiyappan 50 M Labourer 28/06/07 01/08/07
Pain, 
Crepitus, RM
19 8456 Bhanumathi 40 F
House 
wife
02/07/07 07/08/07
Pain, 
swelling, RM
20 8673 Chandra 55 F
House 
wife
02/07/07 07/08/07
Pain, 
swelling, RM
21 8692 Malliga 55 F
House 
wife
02/07/07 07/08/07
Pain, 
Crepitus, 
swelling, RM
22 1674 Lakshmi 48 F
House 
wife
03/07/07 14/08/07
Pain, 
Crepitus, 
swelling, RM
23 8995 Gowri 62 F
House 
wife
03/07/07 14/08/07 Pain, RM
24 9032 Shanthi 41 F
Servant 
Maid
03/07/07 17/08/07
Pain, 
swelling, RM
25 9304 Jothi 47 F Cook 04/07/07 17/08/07
Pain, 
Crepitus, RM
26 9371 Usha 48
House 
wife
04/07/07 17/08/07F
Pain, 
Crepitus, RM
27 9391 Sivaneswari 55 F
House 
wife
04/07/07 09/08/07
Pain, 
Crepitus, 
swelling, RM
28 9417 Padmavathi 53 F
House 
wife
04/07/07 17/08/07
Pain, 
Crepitus, 
swelling, RM
29 9494 Radha 49 F
House 
wife
04/07/07 15/08/07
Pain, 
Crepitus, 
swelling, RM
30 9479 Deivanai 54 F Cook 04/07/07 09/08/07
Pain, 
Crepitus, 
swelling, RM
31 9654 Neela 45 F
House 
wife
05/07/07 10/08/07
Pain, 
Crepitus, 
swelling, RM
32 9673 Jenova 47 F
Fish 
Vendor
05/07/07 09/08/07
Pain, 
Crepitus, 
swelling, RM
Narrowing of jt. Space
Osteophytes
Osteophytes
Osteophytes
Osteophytes
Osteophytes
Narrowing of Jt. Space
Osteophytes
Osteophytes
Narrowing of jt. Space
Osteophytes
Narrowing of Jt. Space
Osteophytes
Osteophytes
Narrowing of Jt. Space
Soft tissue swelling
Narrowing of jt. Space
Osteophytes
Narrowing of Jt. Space
Osteophytes
Narrowing of Jt. Space
Osteophytes
Narrowing of Jt. Space
Soft tissue swelling
Moderate
Moderate
Good
Good
Good
Moderate
Good
Moderate
Moderate
Moderate
Good
Good
Moderate
Good
Moderate
Poor
X-ray
TC Sug-R Chl Urea
cells/cu.mm P L E 1/2hr 1hr mg/dl mg/dl mg/dl
Duration Urine
Sex
Occup-
ation From 
S.
No
OP.
No
Name Age
Blood
To
Compliants Stage ResultsDC - % ESR - mm
Alb Sug Dep KJ
Before 9700 58 36 6 15 34 138 173 20 Nil Nil Few Epicells
After 9400 60 35 5 13 22 108 178 18 Nil Nil Few Epicells
Before 10300 60 33 7 34 60 87 182 19 Nil Nil Few Epicells
After 9400 59 35 6 18 24 96 152 17 Nil Nil Few Epicells
Before 10800 62 33 5 11 20 83 177 22 Nil Nil Few Epicells
After 9600 56 40 4 10 13 98 142 20 Nil Nil Few Epicells
Before 9100 54 41 5 40 84 163 118 18 Nil Nil Few Epicells
After 9600 67 30 3 17 22 162 179 18 Nil Nil Few Epicells
Before 9100 53 41 6 38 70 98 170 18 Nil Nil Few Epicells
After 9200 56 42 2 18 27 104 180 18 Nil Nil Few Epicells
Before 10600 63 29 8 12 20 113 213 23 Nil Nil Few Epicells
After 10200 52 44 4 7 12 89 198 20 Nil Nil Few Epicells
Before 10600 62 32 6 24 40 120 182 18 Nil Nil Few Epicells
After 9800 56 40 4 13 18 118 180 18 Nil Nil Few Epicells
Before 9000 62 34 4 10 14 140 162 23 Nil Nil Occ Puscells
After 9200 52 45 3 5 12 135 163 20 Nil Nil Occ Puscells
Before 9000 59 35 6 30 60 86 169 23 Nil Nil Few Epicells
After 9000 64 34 2 9 16 92 172 20 Nil Nil Few Epicells
Before 8800 61 34 5 25 50 85 177 2 Nil Nil Occ Puscells
After 9000 58 38 4 14 23 112 168 20 Nil Nil Few Epicells
Before 9000 61 34 5 15 32 104 120 23 Nil Nil Occ Puscells
After 9400 62 33 5 10 17 113 142 20 Nil Nil Few Epicells
Before 7900 56 37 7 9 21 82 120 24 Nil Nil Occ Puscells
After 8800 58 39 3 13 18 102 128 20 Nil Nil Few Epicells
Before 9400 63 30 7 12 25 125 179 23 Nil Nil Few Epicells
After 9600 64 40 6 10 20 118 172 22 Nil Nil Few Epicells
Before 10200 64 31 5 12 25 120 192 23 Nil Nil Few Epicells
After 9600 58 36 6 12 18 122 188 20 Nil Nil Few Epicells
Before 10000 62 28 10 10 20 140 182 33 Nil Nil Few Epicells
After 9600 64 40 6 6 14 132 179 28 Nil Nil Few Epicells
Before 9800 54 35 6 20 44 103 195 19 Nil Nil Occ Puscells
After 9400 60 36 4 10 15 98 182 18 Nil Nil Few Epicells
33 9708 Mohan 42 M Labourer 05/07/07 17/08/07 Pain, RM
34 9728 Selvi 42 F Tailor 05/07/07 14/08/07
Pain, 
Crepitus, 
swelling, RM
35 9872 Pankajam 65 F
House 
wife
05/07/07 06/08/07
Pain, 
Crepitus, 
swelling, RM
36 41 Kaladevi 48 F
House 
wife
06/07/07 17/08/07
Pain, 
swelling, RM
37 1071 Saroja 46 F
House 
wife
09/07/07 18/08/07
Pain, 
swelling, RM
38 2590 Yuvarani 45 F
House 
wife
13/07/07 18/08/07
Pain, 
swelling, RM
39 3533 Tamil Mani 48 M Labourer 16/07/07 22/08/07
Pain, 
swelling, RM
40 3532 Jambukeshwar 60 M carpenter 16/07/07 28/08/07
Pain, 
Crepitus, 
swelling, RM
41 3684 Kanniyamma 66 F
House 
wife
16/07/07 15/08/07
Pain, 
Crepitus, 
swelling, RM
42 5683 Kuppammal 44 F
Servant 
Maid
16/07/08 15/08/07
Pain, 
Crepitus, 
swelling, RM
43 4927 Victor 42 M Painter 19/07/07 28/08/07
Pain, 
swelling, RM
44 2223 Jayalakshmi 63 F
House 
wife
09/08/07 15/09/07
Pain, 
Crepitus, 
swelling, RM
48 7662 Kasthuri 56 F Labourer 16/11/07 31/12/07
Pain, 
Crepitus, 
swelling, RM
45 6753 Lakshmi 50 F
House 
wife
12/11/07 21/12/07
Pain, 
Crepitus, 
swelling, RM
46 6311 Muthulakshmi 42 F
House 
wife
12/11/07 10/12/07
Pain, 
Crepitus, 
swelling, RM
47 6294 Kamatchi 60 F
House 
wife
12/11/07 10/12/07
Pain, 
Crepitus, RM
Osteophytes
Osteophytes
Narrowing of Jt. Space
Osteophytes
Narrowing of Jt. Space
Osteophytes
Osteophytes
Narrowing of jt. Space
Osteophytes
Osteophytes
Osteophytes
Narrowing of Jt. Space
Osteophytes
Osteophytes
Osteophytes
Narrowing of Jt. Space
Osteophytes
Osteophytes
Osteophytes
Narrowing of jt. Space
Good
Good
Moderate
Good
Good
Good
Good
Good
Good
Good
Good
Moderate
Good
Moderate
Good
Good
X-ray
TC Sug-R Chl Urea
cells/cu.mm P L E 1/2hr 1hr mg/dl mg/dl mg/dl
Duration Urine
Sex
Occup-
ation From 
S.
No
OP.
No
Name Age
Blood
To
Compliants Stage ResultsDC - % ESR - mm
Alb Sug Dep KJ
Before 10200 64 31 6 12 20 142 170 20 Nil Nil Occ Puscells
After 10000 52 32 6 8 14 133 158 20 Nil Nil Few Epicells
Before 10700 64 30 6 25 54 108 177 18 Nil Nil Few Epicells
After 10300 58 36 6 18 26 112 170 18 Nil Nil Few Epicells
Before 10200 63 32 5 5 9 122 129 21 Nil Nil Occ Puscells
After 9800 66 29 5 7 16 108 132 20 Nil Nil Few Epicells
Before 8700 53 41 6 18 40 93 209 28 Nil Nil Few Epicells
After 8600 58 37 5 13 28 89 212 24 Nil Nil Few Epicells
Before 9200 62 38 5 11 20 92 120 16 Nil Nil Few Epicells
After 9400 59 38 3 7 18 104 132 14 Nil Nil Few Epicells
Before 9800 61 33 6 11 15 86 196 21 Nil Nil Few Epicells
After 9600 64 31 5 4 12 110 180 20 Nil Nil Few Epicells
TC Total WBC Count Sug  - R Sugar Random RM Restricted Movements
DC Differential Count Chl Cholestrol KJ Knee Joint
P Polymorphs Alb Albumin jt. Joint
L Leucocytes Dep Deposits
E Eosinophils
ESR Ertthrocyte Sedimentation Rate
49 4884 Soundararajan 50 M Labourer 17/12/0717/11/07
Pain, 
Crepitus, RM
50 30 Meena 50 F Nil 23/11/07 21/12/07
Pain, 
Crepitus, RM
51 376 Dhanalakshmi 41 F
House 
wife
03/12/07 25/01/08
Pain, 
Crepitus, RM
52 7069 Krishnamurthy 69
25/01/08
Pain, 
Crepitus, 
swelling, RM
M Farmer 12/12/07 25/01/08
53 6979 Sundarambal 60
54 8826 Karunamurthy 50
Pain, 
Crepitus, RM
M Nil 17/12/07 28/01/08
Pain, 
Crepitus, RM
F
House 
wife
12/12/07
Osteophytes
Osteophytes
Narrowing of Jt. Space
Osteophytes
Narrowing of Jt. Space
Osteophytes
Osteophytes
Narrowing of Jt. Space
Narrowing of jt. Space
Good
Good
Good
Good
Good
Good
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Clinical assessment: 
The clinical study was subjected to 60 selected cases. 6 patients with drew 
from the treatment. The following parameters were observed during the course of 
treatment. 
 Age 
 Sex 
 Socio – economic status 
 Occupational status 
 Clinical features 
Age:  
Amongst 54 patients, 33 belonged to 40 to 50 years group, 14 belonged to 51 
to 60 years group and 7 were above 60 years. The percentage chart is as follows. 
Age wise Population
61%
26%
13%
0%
10%
20%
30%
40%
50%
60%
70%
% Population 61% 26% 13%
40 to 50 51 to 60 > 60
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Sex: 
Amongst 54 patients, 17 patients are males and 37 are females. The percentage 
ratio is as follows: 
Male-Female Ratio
0%
20%
40%
60%
80%
% Population 31% 69%
Male Female
Socio Economic Status: 
Amongst 54 patients, 32 patients were poor, 20 in Lower middle class and 2 in 
upper middle class. There were none in rich class. The percentage in the above 
classification is as follows. 
Economic Status
0%
10%
20%
30%
40%
50%
60%
70%
% Population 59% 37% 4%
Poor Lower Middle Upper Middle
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Personal Habits and diet: 
Out of 54 patients 12 were vegetarians and 35 were mixed. 4 were smokers and 
3 alcoholic. The percentage composition is as follows: 
Personal Habits
0%
10%
20%
30%
40%
50%
60%
70%
% Population 22% 65% 7% 6%
Vegetarian Mixed Smokers Alchoholic
Occupational Status: 
Out of 54 patients, 2 were employed in regular employment, 29 were house 
wives, 13 engaged in unorganized sector, 8 were small vendors and 2 were 
unemployed. The percentage composition is as follows: 
Occupational Status
0%
10%
20%
30%
40%
50%
60%
% Population 4% 54% 24% 15% 4%
Employed House Wife Unorganised Small Vendors No employment
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Improvement in Pain: 
The no. of patients reported moderate pain, which affects task as per VAS were 
34 and who reported moderate pain hindering concentration were 20. After the 
treatment, 30 reported no pain and 23 mild pain. The results are as follows: 
Pain -  No of Cases in Different Scales
0
10
20
30
40
VA Scale
N
o
. 
o
f
 c
a
s
e
s
Before 0 0 34 20
After 30 23 1 0
No pain mild pain
moderate (hinder 
task)
moderate (hinder 
concentration)
Descriptive Statistics for Pain 
 Mean Standard Deviation Standard Error of Mean 
Pain before treatment 
Pain after treatment 
4.74 
0.52 
0.97 
0.72 
0.13 
0.001 
From the table we calculated the descriptive statistics like Mean, S.D., and S.E. 
of Mean for the pain score before and after treatment. 
T-Table 
 Mean Standard 
Dev. 
S.E t-value p-value 
Pre vs. Post 4.22 1.02 0.14 30.37 0.000 
From the above table we got a significant difference (p< 0.05), so we conclude 
that there is an improvement between before and after treatment. 
36
The percentage improvement in pain ranged from high level to moderate level. 
Improvement %  in Pain 
0%
20%
40%
60%
80%
Level of Improvement
%
 o
f 
p
o
p
u
la
ti
o
n
% of Population 33% 65% 2% 0%
High level of 
improvement 
Moderate 
Improvement
Mild improvement No improvement
Improvement in Crepitus: 
One patient showed improvement where the others did not show any 
improvement. The percentage improvement is as follows: 
Crepitus Improvement
Improvement, 2%
No Improvement, 
98%
0%
20%
40%
60%
80%
100%
120%
 % of Improvement 2% 98%
Improvement No Improvement
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Improvement in Restricted Movement: 
36 patients showed major improvement and 4 patients showed moderate 
improvement. 10 patients showed only mild improvement and 4 patients did not show 
any improvement. The percentage composition is as follows: 
Descriptive Statistics for Restricted Movement 
 Mean Standard Deviation Standard Error of Mean 
RM before treatment 
RM after treatment 
65.11 
119.56 
30.51 
10.61 
4.15 
1.44 
From the table we calculated the descriptive statistics like Mean, S.D., and S.E. 
of Mean for the pain score before and after treatment. 
T-Table 
 Mean Standard 
Dev. 
S.E t-value p-value 
Pre vs. Post 54.44 25.19 3.43 15.89 0.000 
From the above table we got a significant difference (p< 0.05), so we conclude 
that there is an improvement between before and after treatment. 
Improvement in Restricted Movement
67%
7%
19%
7%
0%
10%
20%
30%
40%
50%
60%
70%
% Improvement 67% 7% 19% 7%
Major Moderate Mild improvement No improvement (0)
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Improvement in Swelling: 
For 19 patients the swelling reduced by more than 2 cm and for 13 patients the 
swelling reduce by 1 cm to 2 cm. 22 patients did not had any swelling. The percentage 
composition is as follows: 
Descriptive Statistics for Swelling 
 Mean Standard Deviation Standard Error of Mean 
Swelling before treatment 
Swelling after treatment 
37.04 
35.84 
3.73 
3.93 
0.51 
0.54 
From the table we calculated the descriptive statistics like Mean, S.D., and S.E. 
of Mean for the pain score before and after treatment. 
T-Table 
 Mean Standard 
Dev. 
S.E t-value p-value 
Pre vs. Post 1.2 0.93 0.13 9.44 0.000 
From the above table we got a significant difference (p< 0.05), so we conclude 
that there is an improvement between before and after treatment. 
Improvement in Swelling
0%
10%
20%
30%
40%
50%
% Improvement 35% 24% 41%
Swelling reduced by > 2 Swelling reduced  by 1 cm No swelling
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5. Discussion 
Hyoscyamus niger. L is known as ‘Kurosaniomam’ in Tamil is a reputed 
drug for Vatha diseases. It is narcotic, sedative, anodyne, antispasmodic, mydriatic 
and useful in many diseases. But in drug markets, different materials are sold as 
kurosaniomam. 
The source drug was identified based on its macro and microscopic characters. 
Seeds are oval or kidney shaped brown with conspicuous characteristic reticulations. 
Odour tobacco like; taste acrid, bitter and oily. 
Anatomically seeds showed important diagnostic structural features such as 
beak shaped radially elongated epidermal cells followed by tangentially extended 
cells, thin walled parenchymatous endosperm containing aleurone grains and oil 
globules. 
Powdered drug was treated with different chemical reagents (Table – 1).  
Florescence Analysis (Table - 2) revealed different shades of green in UV (254nm) 
light except in raw form. 
The preliminary phytochemical analysis showed the presence of oxalate, 
alkaloids, flavonoids, phytosterols, proteins, aminoacids, phenolic compounds and 
tannins. 
The review of literatures showed that Kurosaniomam is a drug for VATHA 
DISEASES. AZHAL KEELVAYU is a more common degenerative disease. Going by 
the anodyne properties of Kurosaniomam, I felt that this can be clinically verified. 
The presence of flavonoids having anti-oxidant property effectively mop up 
the oxidation.27  Thus prevent the cartilage degeneration. Flavonoids also have      
anti-inflammatory action and helps in reducing inflammation.  
The presence of albumin is helpful in binding the serum calcium,31 which is 
essential for maintaining bone mineral density (BMD).  
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Tannins present in Kurosaniomam having astringent property alleviate 
‘Pitha’ in Azhal Keelvayu.   
Terpenoids present in Kurosaniomam exert analgesic and antirheumatic 
properties, 28 which are helpful in the treatment of Azhal Keelvayu. 
The presence of tropane alkaloids hyoscine and hyoscyamine are very 
effective in the pain management. The narcotic property of hyoscine lessens pain
and gives slight somnifacient action.20 The sedative property of these alkaloids 
induces good sleep in patients. 
The acute toxicity study of Kurosaniomam shows, toxicity produced at the 
dose of 1500 mg/kg.
Kurosaniomam churanam shows moderate anti-inflammatory effect at the 
dosage of 150 mg/kg and 300 mg/kg at 120 mts  in formalin induced animal models. 
Analgesic effect lasted for a period of 2 hrs was found to posses significant 
analgesic activity (P<0.001) by Eddy’s hot plate method. 
Clinically Kurosanioma churanam was administered enterally at the dose of 
300 mg, 2 times, with water for 60 patients. Out of which 6 patients withdrew from 
the treatment on various withdrawal criteria. 
 The clinical study results show the female prepondenance of the disease. And 
obesity seen in more than 50% of the female population. 
 Among 54 patients the pain reduced considerably. 33% had high level of 
improvement and 65% had moderate improvement. 
 Among 54 patients swelling got reduced in all the patients who had swelling. 
 Among 54 patients 67% had major improvement and 7% had moderate 
improvement in restricted movements. 
 There was no improvement in crepitus. 
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 Statistical analysis also shows significant p value in pain, swelling and restricted 
movements. 
 2 patients had symptoms of vomiting, palpitation and warm feeling during the 
treatment. Immediately the dose was reduced to 150 mg bd and then they became 
comfortable. But the drug was not discontinued. It was also noted that the patients 
had good sleep during the period of treatment. Remission of pain was also noted in 
10 patients after the completion of 6 weeks treatment. One patient did not show 
any improvement in all the four symptoms. 
‘Karpu suvai’ helps in the relaxation of joint stiffness and alleviates 
“Kapha”29 So Karpu suvai of Kurosanioma Churanam is useful in treating restricted 
movements and alleviates the aggravated ‘Kapha’ humour in Azhlal Keelvayu. 
Kurosaniomam is classified under Saturnine substances. The seat of Saturn in 
our body is thigh and Saturn is responsible for dryness, spasm and restricted 
movement of the legs. So dryness caused by ‘Pitha’; spasm and restricted movements 
caused by ‘Vatha’30 are treated effectively by this drug. 
From the studies and discussion, it is evident that Kurosaniomam is an 
effective drug in the management of pain, swelling and restricted movement in Azhal 
Keelvayu. However the drug is to be used under proper care because of the narcotic 
properties.  
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6. Summary and Conclusion 
 Kurosaniomam (Hyoscyamus niger) is an ingredient in many Siddha preparations. 
This has a wide therapeutic use. However availability of genuine seeds is an issue. 
 The sedative and hypnotic properties of Kurosaniomam help to manage pain in the 
chronic diseases like Azhlal Keelvayu. 
 The acute toxicity of the trial drug is 1500 mg / kg in animal models. 
 Pharmacological study shows Kurosaniomam has moderate anti-inflammatory and 
good analgesic activity. 
 The clinical study clearly demonstrated that pain and swelling have been 
effectively controlled. 
 This being a narcotic drug it needs to be administered under medical supervision. 
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1.   Introduction 
The word Siddha means established truth. The persons who were associated 
with Siddha school of thought were known as Siddhars. Siddhars are considered as 
living saints, who acquired supernatural powers. Siddhars were expert in alchemy. It 
is widely accepted even by Ayurveda experts that Siddha system of medicine contains 
thousands of herbo-mineral formulations which are not found in other Indian System 
of Medicine. Siddha Medicine is not a science of experimental myth or inductive 
generalization based on observations and experiments, it is a divine science evaluated 
by Siddhars by their Siddhis. 
 According to Siddha Principles the physical structures of the universe and 
man are basically made up of five elements and the physiological function of the body 
is mediated and maintained by three forces (Vatham, Pitham & Kapam). In normal 
physiological state they sustain and nourish the body. In diseased state when these 
three forces are vitiated they are called three faults (or) mukkutram. Due to our 
changing life style, food habits and polluted environment, these three forces are 
disturbed, causing diseases. 
One of the commonest diseases due to industrialization and urbanization 
responsible for environmental pollution is “Peenisam”.  The symptoms of Peenisam 
are comparable with sinusitis and allergic rhinitis in modern medicine. Allergic 
rhinitis considered as the commonest allergic disease affecting more than 50% of 
people in India 33 and more than 120 million Indians suffer from atleast one episode of 
acute sinusitis each year. 34
The classic symptoms of Peenisam are sneezing, running nose, nasal 
congestion and head ache. Running nose has a social impact as the sufferer has to use 
hand kerchief all the time. Due to repeated sneezing, nasal congestion and headache 
patient feels fatigue which affects the daily routine. 
There are various medicines available in indigenous and modern medicine. The 
modern medicine prescribes anti-histamines for sneezing and analgesics for headache.  
The well known side effect of anti-histamines is sedation, analgesics is gastric 
44
disturbances and anti-biotics is resistance to the drug when taken repeatedly.  
However it should be noted that these are not curative measures, but management 
measures only. Hence taking these medicines on a routine basis is not advisable.  
In Siddha Medicine there are many preparations are available for Peenisam.  
Karpoora Mezhugu as a curative medicine for Peenisam is not found in these 
practises.  Considering the properties of Karpoora Mezhugu, it was felt that this 
could be one of the effective medicines for Peenisam.  Hence, I have selected the 
drug Karpoora Mezhugu for Peenisam.
Part - 2 
A Study on Karpoora Mezhugu for Peenisam 
Aim & Objective 
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Aim & Objective: 
Aim: 
To assess the efficacy of ‘Karpoora Mezhugu’ in treating ‘Peenisam’. 
Objective: 
The objective of this study is to evaluate the therapeutic efficacy of Karpoora 
Mezhugu in treating Peenisam.  
Karpoora Mezhugu was subjected to the following studies: 
 Phytochemical Analysis 
 Preliminary Bio-Chemical Analysis 
 Antimicrobial Study 
 Acute Toxicity Studies 
 Anti-Inflammatory, Analgesic and Anti-Histaminic Activities 
 Clinical Study 
Part - 2 
A Study on Karpoora Mezhugu for Peenisam 
Review of Literature 
Siddha Classical Reference 
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3.2 Camphor Chemical Aspects 
54
Synonyms 
 1,7,7-Trimethyl Bicyclo (2,2,1)-Heptan-2-One 
 2-Bornanone 
 2-Camphanone 
 2-Keto-1,7, 7-Trimethylnorcamphane 
 2-Oxo-Bornane 
 Alcanfor 
 Camfora 
 Camphor-Natural 
 Camphor-Synthetic 
 Formasa-Camphor 
 Gum Camphor 
 Japan Camphor 
 L,7,7-Trimethy1norcamphor 
 Laurel Camphor 
 Matricaria Camphor 
 Root Bark Oil 
 Spirit Of Camphor 
 Tramfer 
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Physico-Chemical Properties  
Origin of the substance  
Camphor may be natural or synthetic.  It occurs naturally in the wood of the 
camphor tree (Cinnamomum camphora), and is extracted by steam distillation and 
crystallization.  Natural camphor is dextrorotatory.  Synthetic camphor may be made 
from pinene which is converted into camphene by treatment with acetic acid and 
nitrobenzene.  Synthetic camphor is optically inactive. 
     
Chemical structure 
       C10H16O 
       Molecular Weight = 152.2 
                                     CH3
                                           = O 
                                     H3C-C-CH3
Physical properties 
Properties of the substance 
 Normal state at room temperature: solid, translucent crystals. 
 Colour: white crystals. 
 Odour:  penetrating, aromatic. 
 Boiling point: 204 °C 
 Melting point: 176 to 180 °C 
 Sublimes appreciably at room temperature and normal atmospheric pressure 
 Flash point: 65°C 
 Autoignition temperature: 466°C 
 Relative density: 0.99 (specific gravity) 
 Relative vapour density: 5.2 
 Vapour pressure: 20 PA at 20°C 
 Solubility in water: 0.125 g/100 m1 (25 °C) 
 Soluble in ethanol, ethylether, turpentine, and essential oils 
 Relative molecular mass: 152.2. 
Storage conditions 
Store in airtight containers at a temperature not above 25°C. 
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Kinetics 
Absorption by route of exposure 
Camphor is readily and rapidly absorbed from the skin, and gastrointestinal 
and respiratory tracts. Camphor in oil solutions is absorbed slowly from subcutaneous 
or intramuscular depots. 
Distribution by route of exposure 
After oral ingestion, peak blood levels are reached in 5 to 90 min.  The high 
lipid solubility of camphor suggests that it accumulates in adipose and other tissues.  
Camphor crosses the placenta (Kresel, 1982), and has a large volume of distribution. 
Metabolism 
Camphor is rapidly oxidized to campherols (2-hydroxycamphor and 3-
hydroxycamphor), and then conjugated in the liver to the glucuronide form (Kresel, 
1982).  Camphor-related metabolites are relatively fat-soluble and may accumulate in 
fatty tissue. 
Elimination by route of exposure 
Campherol conjugated to glucuronic acid is eliminated mainly in the urine as 
an inactive compound (Kresel, 1982).  Trace amounts are eliminated by the lungs. 
Interactions 
Oils, alcohols, and fats promote gastrointestinal absorption. Although vaseline 
oil has been used for gastric decontamination, its use is controversial. 
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Pharmacology and Toxicology 
Pharmacodynamics 
 Camphor is used exclusively because of its local effects. When rubbed 
on the skin, it acts as a rubefacient and causes localized vasodilatation, 
which gives a feeling of comfort and warmth. 
 As an anti-pruritic agent, when applied gently on the skin, it may create 
a feeling of coolness, and a mild, local anaesthetic effect, which may be 
followed by numbness. 
 When ingested in small amounts, it creates a feeling of warmth and 
comfort in the stomach, but given in large doses it acts as an irritant 
(Goodman et al 1985). 
Toxicodynamics 
 Camphor is a CNS stimulant whose effects range from mild excitation 
to grand-mal convulsions or status epilepticus. These effects result from 
excitation of the cerebrum and lower structures of the CNS. Gastric 
irritation, together with cortical and medullary stimulation, frequently 
causes vomiting and diarrhoea. 
 Other symptoms are: Headache, confusion, vertigo, excitement, 
restlessness, delirium, and hallucinations; increased muscular 
excitability, tremors, and jerky movements; epileptiform convulsions 
followed by depression; convulsions sometimes occur early in cases of 
poisoning and may be severe; coma; CNS depression may at times be 
the primary clinical response. 
 Mydriasis and impairment of vision have been reported. 
 Death results from respiratory failure or from status epilepticus. 
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Toxicity 
Human data 
 Adults: The probable oral lethal dose is 50 to 500 mg/kg.  A dose of 2 g 
generally causes toxic effects in adults.  The potential lethal oral dose in 
adults is 4 g pure camphor. 
 Children: The lethal dose for children is estimated to be 0.5 to 1.0 g 
(Siegel & Wason, 1986); for infants,the oral LDLo is 70 mg/kg. 
 Carcinogenicity: Carcinogenicity tests have been negative. 
 Mutagenicity: Not mutagenic with the Ames test. 
Medicinal Properties and Uses20
 Camphor has stimulant antispasmodic, anti-septic, anti-pyretic and 
aphrodisiac properties. When locally applied it is stimulant and 
anodyne.  
 It is useful in adynamic fevers, inflammation, choleraic diarrhoea, 
whooping cough, epilepsy, chorea, asthma, angina pectoris and 
puerperal convulsions. 
 It is also used in treating hysteria, palpitation, in affection of the genito-
urinary system as dysmenorrhoea, spermatorrhoea. 
 It is also useful in irritable conditions of the nasal mucus membrane
causing sneezing and frontal headache. 
 Used as an anti-dote to strychnine poisoning. 
 Externally it is a useful stimulant to stiff and painful parts and is used in 
chilblains, rheumatism, neuralgic affections, sprains, bruises, bedsores 
and pruritus.  
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3.3  Botanical Aspect 
Root Bark of Mathuzhai (Punica granatum) 
Classification: 
 Kingdom Plant kingdom 
 Class  Dicotyledons 
 Subclass Polypetalae  
 Series  Calyciflorae 
 Order  Myrtales 
 Family Punicaceae 
 Genus  Punica
 Species Granatum
Vernacular names 
5 
 Tamil  Mathuzhai 
 Telugu Danimma 
 Malayalam Matulem 
 Kannada Dalimba 
 Hindi  Anar 
 Gujarathi Dadam 
Habitat 
Found growing wild in the warm valleys and other hills of the Himalayas 
between 900 -1800 m and also cultivated throughout India. 
Description 
A shrub or small tree 5 -10 m high. Bark smooth, dark grey; Branchlets 
sometimes spinescent; leaves 2.0-8.0 cm long, oblong, shinning above; flowers 
usually scarlet red or yellow mostly solitary or 2-4 together; fruits globose, crowned 
by persistant calyx with a coriaceous  woody rind and  interior septate with 
membranous walls containing numerous seeds; seeds are angular with flesh testa 
which is red, pink or whitish. 
Parts used: 
Root bark, stem bark, fruits including rind,leaves and flowers. 
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Chemical constituents and medicinal uses of root bark 
 Organic: Alkaloids, Steroids, Glycosides, Carbohydrates, Phenolic 
compounds, Tannins, Resins. 
 Inorganic: Iron, Sodium, Calcium, Potassium and Phosphate. 
 The root bark contains 22% of punicotannic acid (which gives it the astringent 
property) and a yellow colouring matter.56 The root bark contains a number of 
alkaloids belonging to pyridine group. Isopelletierine is the most prominent alkaloid, 
possess anthelmintic property. The tannate of alkaloids known as pelletierine tannate 
is the most effective because of its insolubility which prevents its rapid absorption and 
thus enables a prolonged contact with worms.  D-Mannitol occurs lesser amounts 
which posseses mild antispasmodic and anthelmintic properties. 57
Extracts, exhibited Antibiotic activity. Aqueous extract of the root bark was 
found to inhibit completely the activity of Mycobacterium Tuberculosis. Alcoholic 
extracts of root bark showed activity against Pyogenes var aureus. 
Over dose of isopelleterine produces complete paralysis, and sometimes 
dizziness.  Excessive doses produce mydriasis, amblyopia, vomiting, diarrhea and 
extensive muscular weakness. 
Studies  on P. granatum:  2002-03 -1634   Immunomodulatory activity of Punica 
granatum in rabbits - Journal of ethno pharmacology V 78(1), pp 85 - 87, year 2001. 
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Valmizhagu (Piper cubeba) 
SYNONYMS  
Cubeba officinalis 
Classification 
 Kingdom Plant Kingdom 
 Class  Dicotyledons 
 Sub Class Monochlamydeae 
 Order  Piperales 
 Family Piperaceae 
 Genus  Piper
 Species Cubeba
Vernacular Names 58 
 Tamil  Valmizhagu 
 Telugu Chalava miriyalu 
 Bengali Kabab chini 
 Hindi  Sheetal chini 
 Sanskrit Kankola 
 English Cubebs, Tailed pepper 
Habitat 
 A native of Java and the Moluccas cultivated to some extent in India. 
Description 
A liana like woody climber. Leaves glabrous, ovate, oblong with cordate or 
rounded base, tapering or shortly acuminate, firmly coriaceous, glaborous or sparsely 
pubescent beneath, lower surface densely provided with minute sunk glands; spikes at 
first terminal but becoming leaf opposed, solitary. Bracts papillose, pubescent above. 
Flowers unisexual; peduncle ½-2 cm ; spikes 3-10 cm; Male bracts oblong, obovate 
1.5-2 mm; stamens 3; female spikes often curved bracts oblong 4-5mm by+ 
8mm;richis of spikes glabrous or near insertion of bract with white longish hairs; 
stigmas 3-5, berry from 3-15 mm; stipitate base globose sordidly orange 6-8 mm in 
diameter; seed globose. 
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Parts Used 
Fruits and its oil 
Chemical Constituents: 
 Organic:  Carbohydrates, phenols, proteins, steroids and tannins. 
 Inorganic: Iron, calcium, lead, magnesium and potassium. 
Action 
 Stimulant 
 Carminative 
 Stomachic 
 Expectorant  
Dosages 
59 
 Powdered drug 1-2 gm 
 Infusion  30-60 ml 
 Oil of cubeb  5-10 drops  
Medicinal Uses 
 Smoking cubebs is a popular method of treating nasal catarrh and hay   
fever. 60
 Powdered long pepper administered with honey will relieve cough, cold, 
asthma,hoarsiness and hiccup.61
 For hoarsiness and catarrh a mixture of long pepper, long pepper root, black 
pepper and ginger in equal parts is a useful combination. 
 In catarrhal fever with difficulty of breathing, a powder made of  equal parts of 
karkatakashingi, and long pepper is given in 1 dracham doses with honey.  
Studies on P. cubeba
2006-01-0104, Effect of some medicinal plants on plasma antioxidant system 
and lipid levels in rats, Phytotherapy Research, V19 (5), Pp 382-386, 2005 
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Kirambu (Syzygium aromaticum) 
Synonyms 
61 
 Myritus carophyllus 
 Caryophyllus aromaticus 
 Eugenia caryophyllata 
 Eugenia aromaticum
Classification 
 Kingdom Plant Kingdom 
 Class  Dicotyledons 
 Sub Class Poly petalae 
 Series  Calciflorae 
 Order  Myrtales 
 Family Myrtaceae 
 Genus  Syzygium  
 Species Aromaticum
  
Vernacular Names 
 Tamil  Kirambu 
 Telugu Karavappu 
 Bengali Lavang 
 Hindi  Laung 
 Sanskrit Lavanga, srisamgyam, devakusumam 
 English cloves 
Habitat 
62 
India and Ceylon  
The clove tree is an evergreen tree which grows to a height ranging from 10 -
20 m, having large oval leaves and crimson flowers in numerous groups of terminal 
clusters. The flower buds are at first pale color and gradually become green, after 
which they develop in to a bright red, when they are ready for collecting. Cloves are 
harvested when 1.5 - cm long, and consist of a long calyx, terminating in four 
spreading sepals, and four unopened petals which form a small ball in the centre. 
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Parts used: 
Fruit, dried flower buds and oil. 
Active compounds: 61  
The compound responsible for the cloves aroma is eugenol. It is the main 
component in the essential oil extracted from cloves, comprising 72-90%. Eugenol 
has antiseptic and anesthetic properties. Other important constituents include 
essential oils acetyl eugenol, beta-caryophylline and vanillin; crategolic acid, tannins, 
gallotannic acid, methyl salicylate (pain killer); the falvanoids eugenin, kaempferol, 
rhamnetin, and eugenitin; triterpenoids like oleanolic acid, stigmasterol and 
campesterol; and several sesquiterpenes. 
Actions: 
 Stomachic 
 Carminative 
 Stimulant 
 Aromatic 
 Antispasmodic 
Medicinal uses 
 Cloves as are used as a carminative, to increase hydrochloric acid in the 
stomach and to improve peristalsis. 
 Cloves are natural Anthelmintic. 
 A paste made of cloves applied to the forehead and to the nose-
bridge is a popular remedy in headache and coryza. 
 Oil internally increases circulation, promotes digestion of fatty and 
crude food, promotes nutrition and relieves gastric and intestinal pains 
and spasms. 
 It stimulates the skin, salivary glands, kidneys, liver and bronchial 
mucus membrane.  
 The oil is used as an anodyne for dental emergency.
 Oil is used as an application in rheumatic pains, sciatica, to the head in 
headache. 
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Toxicity: 
62
It is excreted in the breath, perspiration, bile, milk and urine.  
Cloves can be irritating to the gastro-intestinal tract, and should be avoided by 
people with gastric ulcers, colitis or irritable bowel syndrome. In overdoses, cloves 
can cause vomiting, nausea, diarrhoea and upper gastrointestinal hemorrhage. Severe 
cases can lead to changes in liver function, dyspnea, and loss of consciousness, 
hallucination and even death. The internal use of the essential oil use can cause severe 
kidney damage. 
Studies  On S.aromaticum
 Antimicrobial screening of some Indian species (clove), Phytotherapy research 
V 13 (7) Pp 616-618, 1999 
 2000-02-0995 – Antimicrobial activity of Jordanian medicinal plants. 
Pharmaceutical biology V 37(3) Pp 196-201, 1999.The most susceptible 
bacteria were Pseudomonas aeruginosa, Bacillus aureus and Streptococcus 
pyogenes. 
 Invitro evoluation of antioxidant activity of essential oils and their 
components, Flavour and Fragrance journal V 15 (1) Pp 12-16 2000 
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Elumichai (Citrus acida) 
Synonyms 
63
 Citrus medica,  
 Citrus aurantifolia,  
 Citrus bergamia 
Classification 
 Kingdom Plant Kingdom 
 Class  Dicotyledons 
 Sub Class Poly petalae 
 Series  Disciflorae 
 Order  Geraniales 
 Family Rutaceae 
 Genus  Citrus 
 Species Acida 
  
Vernacular Names 
 Tamil  Elumichai 
 Telugu Nimma 
 Kannada Limbe, Nimbe 
 Malayalam Erumichinarkam 
 Sanskrit Jambira 
 English Lime 
Habitat 
64
 Found in tropical parts of India, including the tropical valleys of 
Himalayas and Khasi mountains. Cultivated in WestBengal, UttarPradesh, Delhi, 
Punjab, MadhyaPradesh, Maharashtra, Karnataka, AndraPradesh and Tamil.Nadu. 
Description 
  A thorny shrub or small bushy tree; leaves coriaceous, persistent with 
winged petioles. Leaflets elliptic, oblong or ovate, lanceolate, acute or obtuse; flowers 
small, white or pinkish, 5-10 in a raceme; fruits globular, ovoid or oblong, often 
mamillate at the apex, rind thin tightly attached, green or spotted with yellow green 
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spotted with yellow when ripe, pulp yellowish green acidic and aromatic. Flowers in 
April – May and fruits in May –June.  
Parts used: 
Fruits and leaves.  
Actions: 
61
 Refrigerant 
 Antiscorbutic 
 Antiseptic 
 Germicide 
 Febrifuge 
 Digestive 
 Stomachic 
 Anthelmintic 
Constituents: 61, 65
Ascorbic acid, phosphoric and malic acids, calcium, phosphorus, iron, sodium, 
citrates of potassium, vitamin A, thiamine, riboflavin, niacin, mucilage and ashes. 
Medicinal uses: 
 Hot lemon juice is useful in colds and mild forms of influenza. For a bad cold, 
the juice of 2 lemons in a pint of boiling water sweetened to taste and taken at 
bed time acts like magic 
 It is also a preventive of influenza and of any tendencies to pneumonia. 
 Lemon juice, ginger juice, rock salt, black salt and sonchal salt in equal parts 
mixed together and warmed is used as  a snuff for promoting discharge of 
phlegm in fevers, complicated with pain in the head, throat and chest. 
 It is an antidote which should always be first tried. 
 Lime juice is most useful in dysentery with sloughing of the mucus 
membranes. 
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Karumbu Vellam (Saccharum officinarum) 
 Vellam is a product obtained on concentrating sugarcane juice with or with 
out prior purification into a solid or semi sold state.  It is produced almost throughout 
India and forms an important item of the Indian diet. 66
Classification 
 Kingdom Plant Kingdom 
 Class  Monocotyledons 
 Series  Glumaceae 
 Family Gramineae 
 Genus  Saccharum 
 Species Officinarum 
Vernacular Names 
 Tamil  Vellam 
 Telugu Bellanim    
 Kannada Bella    
 Malayalam Vella    
 Hindi  Gur    
 English Jaggery    
Actions: 
 Preservative 
 Demulcent 
 Antiseptic 
 Pectoral 
78
Constituents: 
67
  
Parameter Value 
Fibre 0.0  g 
Ash 1.1  g 
Calcium 80   mg 
Phosphorous 60   mg 
Iron 2.4   mg 
Thiamine 0.02 mg 
Riboflavin 0.07 mg 
Niacin 0.3 mg 
Ascorbic Acid 3 mg 
Medicinal Uses:  
 Jaggery purifies the blood, prevents rheumatic afflictions and disorders 
of bile, regularizes blood flow and enriches the bone marrow, blood, 
fat, flesh and phlegm. 
 Jaggery is known to improve throat conditions, normalizing semen and 
sperms, serving as a lactogenic and cardiac tonic. 
 It also known to have effect in anemia, jaundice, breathlessness, and 
kidney problems.  
 Reported to have effect on countering ill-effects of pollution.  
Studies Made On S. Officinarum
2006-02-0660, Radio protective effect of sugarcane extract in chickens. 
Phytotherapy Research V19 (6): Pp496-500, 2005. 
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Karpooram
Lime Juice
Mathuzhai
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4. Materials, Methods and Results 
4.1  Preparation of the test drug: 
 The Karpoora Mezhugu was selected from the literature “Kannusamy Pillai 
Parambarai Vaithyam” 
The required raw drugs Karpooram, Valmizhagu, Kirambu, Karumbu Vellam 
were procured from the raw-drug shop in Chennai. Mathuzhai Verpattai was collected 
at Alangulam in Tirunelveli District. Lemon was procured from the local market. 
Karpooram, Valmizhagu, Kirambu, Mathuzhai Verpattai - each 35 g, Karumbu 
Vellam – 140 g, Lime juice 50 ml, is the composition for the preparation of the trial 
drug. 
Valmizhagu, Kirambu and Mathuzhai Verpattai were finely powdered 
individually and kept.  
Lime juice was taken in a used earthen plate. Powdered camphor was added to 
the juice. Then the plate was placed in flame till creamy consistency was attained.  
This was cooled and poured in a clean kalvam and the above mentioned powdered 
drugs were added and were ground together. To this Karumbu Vellam was added and 
blended till it attains a waxy consistency. 
Administration of the test drug: 
Dose:   400 mg  
Route:  Enteral  
Vehicle:  Water 
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4. 2   Bio-Chemical Analysis: (Dept of Bio Chemistry, GSMC, Chennai)
Preparation of Extract: 
5 gm of Karpoora  mezhugu is weighed accurately and placed in 250 ml clean 
beaker and 50 ml of distilled water is added. Then it is boiled for about 10 minutes. 
After which it is cooled and filtered in a 100 ml volumetric flask and made up to     
100 ml with distilled water. 
Table – 1 
Sl.No Experiment Observation Inference 
I Test for acid radicals   
1) Sulphates 
a) 2 ml of the above prepared 
solution was taken in a test 
tube. To this 2 ml of 4% 
Ammonium oxalate solution 
was added. 
Cloudy appearance Presence of 
sulphate 
b) 2 ml of the above prepared 
solution was taken in a test 
tube. To this 2 ml of sodium 
carbonate extract was added 
with 2 ml of dilute HCL until 
the effervescence ceases off. 
Then 2 ml of Barium 
Chloride solution was added.   
A White precipitate 
insoluble in 
concentrated HCL 
was obtained 
Presence of 
Sulphate was 
confirmed 
2 Chloride 
 2 ml of Sodium Carbonate 
extract was added with dilute 
Nitric Acid till the 
effervescence ceases. Then 2 
ml of Silver nitrate  solution 
was added.  
Cloudy white 
precipitate 
completely soluble 
in excess of 
ammonium 
hydroxide solution 
Presence of 
chloride 
3 Oxalates 
 5 drops of clear solution was 
added with 2ml of dilute 
sulphuric acid and slightly 
warmed. To this, 1 ml of 
dilute potassium 
permanganate solution was 
added. 
Potassium 
permanganate 
solution was 
decolourised  
Presence of 
oxalate.  
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Table – 1 (cont…)
Sl.No Experiment Observation Inference 
II Test for Basic Radicals 
4 Aluminium 
 To the 2 ml of extract, 
Sodium Hydroxide solution 
was added in drops to excess 
White precipitate 
observed soluble in 
excess of sodium 
hydroxide was 
obtained 
Presence of 
Aluminium 
5 Calcium 
 2 ml of Extract was added 
with 2 ml of 4% Amonium 
Oxalate solution  
Cloudy appearance Presence of 
Calcium 
6 Magnesium 
 To the 2 ml of extract, 
Sodium Hydroxide solution 
was added in drops to excess 
White precipitate 
observed soluble in 
excess of sodium 
hydroxide was 
obtained 
Presence of 
Magnesium 
Results:  
 Acid Radicals: Sulphate, and Chloride 
 Basic Radicals: Aluminium, Calcium and Magnesium 
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4.3  Preliminary Phytochemical Analysis 
This study was carried out at Vel's College of Pharmacy, Velan Nagar, 
Pallavaram Chennai - 600 117 Tamil Nadu, India.  
The following tests were done: 
 For Alkaloids - Mayer’s Test, Dragendroff’s Test. 
 For Carbohydrates And Glycosides - Molisch’s Test, Borntrager’s Test. 
 For Cardiac Glycosides - Legal’s Test, Keller-Killiani Test.  
 For Sugars - Fehling’s Test, Benedict’s Test. 
 For Steroids - Liebermann’s Burchard Test, Salkowski Test.  
 For Tannins. 
 For Proteins - Millon’s Reagent, Biuret Test, Ninhydrin Test, Xanthoprotein 
Test. 
 For Terpenoids -  Noller’s Test.  
 For Flavonoids - Shinoda Test.  
 For Anthocyanins. 
 For Quinones. 
Preliminary phytochemical Results 
Preliminary phytochemical screening revealed the presence of Sugar, Tannins, 
Flavonoids, Triterpenoids and Steroids.  
Part - 2 
A Study on Karpoora Mezhugu for Peenisam 
Materials, Methods and Results 
Antimicrobial Study 
Anti microbial Study
83
4.4  Antimicrobial Study 
The following microorganisms were used for the study. Standard strain of 
Staphylococcus aureus, Esherichia coli, Klebsiella pneumoniae, Pseudomonas 
aeruginosa, Proteus vulgaris, Candida albicans. These micro-organisms were 
obtained from the laboratory stock of the Department of Pharmaceutical 
Biotechnology, Vel’s college, Pallavaram.  
Antimicrobial Study  Results 
The minimum inhibitory concentrations (MICs) of the Karpoora Mezhugu
against the test organisms are shown in Table 2. The Karpoora Mezhugu showed 
activity against Staphylococcus aureus was found to be excellent. But the activity 
against proteus was moderate and effective at median dose level (Table-2).  In 
general, the gram positive organisms are more sensible than others. The MIC was 
20µg /ml against both the clinical isolates of Staphylococcus aureus, Candida 
albicans, and 20 & 30µg/ml against proteus vulgaris and Pseudomonas aeruginosa. 
The control did not produce any inhibitory activity against the organisms. The zone of 
inhibition produced by 30µg /ml of the Karpoora Mezhugu was 16mm against 
Pseudomonas, 12mm against S. aureus and 16mm against the clinical isolates of
Proteus. The zone of inhibition produced by Karpoora Mezhugu against standard 
strains of Candida, Esherichia coli, Klebsiella pneumoniae was much lower or 
negligible (3mm). 
In vitro antimicrobial activity of 10, 20, 30µg /ml of the Karpoora Mezhugu. 
Table - 2
Mean diameter of zone of inhibition in mm Organisms 
Control 10µg/ml 20µg/ml 30µg/ml
Esherichia coli  0 0 0 0 
Klebsiella pneumonia 0 0 0 0 
Pseudomonas aeruginosa 0 0 0 16 
Staphylococcus aureus 0 6 8 12 
Proteus vulgaris 0 0 6 16 
Candida albicans  0 0 0 0 
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4.5  Pharmacological Studies 
Animals 
Albino mice were used in this study; they were maintained under standard 
animal house conditions, fed on commercial feed pellet, and water ad libitum. All 
experimental protocols were approved by IAEC.  
Acute toxicity 
Healthy albino mice of either sex, weighing around 22-28 g, and overnight- 
fasted, were used for study. Food was withdrawn during the study, however free 
access to water was provided. The weighed animals were randomly assigned to seven 
groups of six animals each (n=6), and were administered the Karpoora Mezhugu 
orally, in the increasing doses 50, 100, 500, 1000, 2000 and 4000 mg/kg. (Table-3)  
Acute toxicity Results 
The animals showed minor changes in general behaviour or other 
physiological activities. The symptoms like continuous grooming, aggressive 
behaviour at high dose range, not responding to stimuli, sedation, muscle twitch in all 
the group and hyperactivity at 15th minute after drug treatment, convulsion, diarrhoea 
(45th min), writhing was generally observed in the above 500mg/kg dosed animals. 
Death was recorded during the treatment period in treated groups given 2-4g/kg of 
Karpoora mezhugu orally. So, it can be concluded that a test substance is practically 
toxic after an acute exposure at the dose range of 4g/kg. 
Neither toxicity signs nor behavioural changes observed up to 4000 mg/kg.  
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Incremental dose finding experiment and its Signs of Toxicity  
Table-3 
Treatment 
Group 
Dose 
Mg/kg
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 
I 50 + - - + + + + + - - - - - - - - - - - - 
II 100 + - - + + + + + - - - - - - - - - - - - 
III 250 + - - + + + + + - - - - + - - - + - + - 
IV 500 + - + + + + + + - - - - + + - - + - + - 
V 1000 + + + + + - + + - - + - + + - + ++ - + - 
VI 2000 + + + + + - + + - + + - + + - + ++ + + + 
VII 4000 + + + + - - - + 1+ + - - - - - + ++ + ++ +++ 
1. Alertness 2. Aggressiveness 3. Pile erection 4. Grooming 5. Gripping 6. Touch 
Response 7. Increased Motor Activity 8. Tremors 9. Convulsions 10. Muscle Spasm 
11. Catatonia 12. Muscle relaxant 13. Hypnosis 14. Analgesia 15. Lacrimation 16. 
Exophthalmos 17. Diarrhoea 18. Writhing 19. Respiration 20. Number of Deaths 
(Mortality) 
Anti-inflammatory study 
Anti-inflammatory study was carried out in formalin induced paw edema in 
Wistar rats. Overnight-fasted Wistar rats were randomly assigned to three groups 
(n=6). Such animals received orally adjuvant, diclofenac, or the Karpoora Mezhugu. 
Inflammation was produced in these animals by injection of 0.1 ml of 1% w/v 
formalin into the subplantar region of left hind paw. The paw volume was measured 
using mercury displacement technique, with the help of plethysmograph at 0, 30, 60 
and 120 minutes after formalin injection. The difference between 0 and 2h reading 
were taken as the volume of edema and percentage of edema inhibition, and was 
calculated for each group. The results are summarised as shown in Table 4. 
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Anti-inflammatory activity results 
The formalin causes a local injury of the paw, is used as a model for pain, and 
localized inflammatory pain. There are two phases of responses, while the stimulus 
during the early phase is a direct chemical stimulation of nociceptors, and that during 
the late phase, involves inflammation. Formalin-induced pain is caused primarily by 
peripheral tissue inflammation. Acute inflammation may last for relatively shorter 
duration, ranging from few minutes to few days. Exudation of fluid and plasma 
proteins, emigration of leukocytes, and predominantly neutrophils, are characteristic 
changes. The Karpoora mezhugu as well as diclofenac showed antiphleogestic 
activity. This antiinflammatory activity was found to be statistically significant 
(P<0.05) at the concentration of 400 mg/kg and 800 mg/kg after 60minutes of drug 
treatment (Table 4).  
Anti-inflammatory Effect of Karpoora Mezhugu  
Table - 4 
Group                      Dose(mg/kg) 
Increase in  
paw volume 
(ml) 
% inhibition 
Control  2 ml/kg  0.90 ± 0.22         - 
Diclofenac Na  150  0.23 ± 0.03  75.7 ± 2.18*  
K.M.  400  0.73 ± 0.05  19.0 ± 3.21*  
K.M.  800 0.71 ± 0.05 21.6 ± 0.56*  
Values are mean ± SE of six animals in each group, *P<0.05 when compared to 
control  
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Analgesic activity 
Eddy’s hot plate method 
In this method, the pretested Swiss mice (reaction time: 2-4 sec) were assigned 
randomly into two groups of six animals each (n=6). The Karpoora Mezhugu was 
dissolved in water, and was administered orally. The delay in reaction time (hind paw 
licking/jump response) of animals, when placed on hot plate maintained at 55°±1 
(Eddy’s analgesiometer, INCO), was recorded and tabulated. The pain threshold is 
considered to be reached when the animals lift and lick their paws or attempt to jump 
out of the hot plate covered with Acrilic fiber door. The time taken for the rat to 
exhibit these characteristics (time reaction) was noted by means of a stopwatch. The 
animals were tested before and 15 min, 30 min, 45 min and 60 min after drug 
administration. A cut-off time was fixed at 15 sec, to avoid damage to the paws. 
Pentazocin, 5 mg/kg was used as standard analgesic. The results are summarised as 
shown in Table 5 
Analgesic activity Results 
In the thermal method, the Karpoora Mezhugu treated animals (400 and 800 
mg/kg) exhibited statistically significant elevation in mean basal reaction time. Effect 
of Karpoora Mezhugu is almost comparable to that of standard drug. This point to the 
involvement of higher centre in the analgesic activity. However, it was less effective 
than standard drug, Pentazocin.   
Karpoora Mezhugu in the doses of 400 and 800 mg/kg body weight, increased 
reaction time in a dose-dependent manner. The results were statistically significant 
(P<0.05).  
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Analgesic Activity of Karpoora Mezhugu by Eddy’s hot plate Method  
Table -5 
Group    Dose 
(mg/kg)  
    Mean reaction time  
 (in secs)  
Percentage increase 
in basal reaction 
time  
Adjuvant 
control  
2 ml/kg  3.18±0.51  - 
Pentazocin  5  11.0±0.56  75.5*  
K.M. 400  4.60±0.60  29.8  
K.M.  800  8.50±0.5  59.5*  
    
Values are expressed as mean±SE of six animals, *P<0.05 when compared to control 
Statistical analysis  
Values were expressed as mean ± SEM. The statistical significance was 
analyzed by One-Way ANOVA followed by the Dunnet’s multiple comparison tests 
using INSTAT-3 computer software programme. P<0.05 was considered as 
significant.  
Anti-histaminic activity
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Effect of Karpoora Mezhugu against Histamine in Isolated Guinea Pig Ileum 
Animals:  Adult guinea pig (400-600gms) obtained from King Institute, Chennai was 
used for the experiment. 
Drugs: Histamine acid phosphate was used. 
Test drug preparation:  
The test drug concentration was 100 microgram per ml prepared by dissolving 
with 2% CMC in distilled water. 
Materials and Methods 
Preparation of guinea pig ileum 
Guinea pig was stunned and bled. Segments of the ileum (4 cm long) were 
removed 10 cm from the caecum. The strip was incubated for 30 min before 
constructing concentration-response curves to the test drug. The pH of the stock 
solution was adjusted, before adding to the organ bath, and when in the bath was 
measured. Contact time of drug or standard agonist with the tissue was maintained at 
5 min intervals. 
Results 
The pH of the extract before adding to the organ bath, and in the organ bath 
remained at 7.0. The Karpoora Mezhugu had an antagonistic effect on guinea pig 
ileum. The contractile response was concentration dependent.  
DISCUSSION 
The aim of this study was to determine the effect of Karpoora Mezhugu on 
isolated guinea pig ileum. As low as 1 mg/ml of the test drug produced a response. As 
the pH of the extract before and after adding to the tissue in the organ bath remained 
constant, it is not likely that pH contributed to the activity of the Karpoora Mezhugu.  
Part - 2 
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ABOUT THE DISEASE 
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4.6 Clinical Study 
This was an open non comparative clinical trial 
The clinical study was carried out in Gunapadam Post Graduate Out Patient 
Department, Arignar Anna Hospital, Chennai-106. 
Selection Of Patients 
50 patients were selected in both sexes. The selection of patients was based on 
the following inclusion and exclusion criteria. 
Inclusion Criteria 
 Age-16 - 65 
 Sex – both male and female  
 Sneezing 
 Rhinitis 
 Nasal congestion 
 Pain 
Exclusion Criteria  
 Fever   
 Common cold  
 Nasal polyps  
 Migraine head-ache 
Withdrawal Criteria  
 Irregular treatment  
 Patients who followed dual treatment 
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Treatment Schedule  
 Karpoora mezhugu 400 mg two times a day after food 
 Vehicle-water  
 Route of administration-enteral route  
 Duration -6 weeks 
    
Study Procedures  
50 patients were selected for clinical trial on the basis of inclusion criteria. For 
all the cases full clinical data was recorded and they were diagnosed on the basis of 
Siddha principles and Modern parameters. The patients were followed up for 6 weeks 
and the evaluation was recorded at the end of each week and a complete clinical and 
the following lab investigations were done at the first week and at the end of the 6th 
week. 
 Urine routine  
 Blood    
o TC,DC, ESR  
o Sugar -  Random, cholesterol, Urea 
 X- ray Para nasal sinuses  
Medical Advice And Diet 
 The patients were advised,  
 To avoid known allergens like  inhalation of dust, fumes and aromatic 
substances which trigger sneezing  
 To avoid cold and dusty environment  
 To avoid smoking 
 To drink and bath in warm water and dry hair well after bath 
 To avoid watery vegetables like radish, pumpkin etc. 
 To do yoga and pranayama. 
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Bio-Statistical Analysis: 
The statistical analysis of the clinical observations was analyzed with the help 
of a statistician where the following two tests were conducted to find the significance 
of the results. 
T – Test: The t- test is a statistical test that helps to show if there is a real difference 
between different treatments / phases of treatments, being tested in a controlled 
clinical trial. 
Chi square test:  A statistical test used to determine the probability of obtaining the 
observed results by chance, under a specific hypothesis. 
X-ray
TC Sug - R Chl
cells/cu.mm P L E 1/2hr 1hr mg/dl mg/dl
Before 9400 53 42 5 20 44 124 142 Nil Nil Few epi.cells
After 9200 61 34 5 12 16 112 117 Nil Nil Few epi.cells
Before 9200 64 31 5 3 7 98 113 Nil Nil Occ.puscells
After 9000 66 29 5 5 12 112 120 Nil Nil Few epi.cells
Before 9200 54 41 5 10 22 102 142 Nil Nil Few epi.cells
After 9800 62 34 4 10 12 114 136 Nil Nil Few epi.cells
Before 9200 64 31 5 3 7 132 148 Nil Nil Occ.puscells
After 9200 56 39 5 5 10 128 138 Nil Nil Few epi.cells
Before 8100 63 33 4 8 20 130 118 + Nil Few epi.cells
After 8200 64 34 2 5 12 115 123 Nil Nil Few epi.cells
Before 8600 52 41 7 10 17 96 128 Nil Nil Few epi.cells
After 9200 54 40 6 8 15 113 125 Nil Nil Few epi.cells
Before 9600 52 43 5 12 20 123 148 Nil Nil Occ.puscells
After 9400 60 35 5 7 13 126 136 Nil Nil Occ.puscells
Before 9600 61 32 7 7 10 128 156 Nil Nil Few epi.cells
After 9800 63 34 3 7 12 106 135 Nil Nil Few epi.cells
Before 9600 52 40 8 24 40 114 124 Nil Nil Few epi.cells
After 9400 60 34 6 8 15 98 128 Nil Nil Few epi.cells
Before 9600 55 41 4 12 20 120 136 Nil Nil Occ.puscells
After 9200 62 34 4 7 12 125 126 Nil Nil Few epi.cells
Before 9800 53 45 6 11 25 113 138 Nil Nil Few epi.cells
After 9800 58 37 5 11 17 126 123 Nil Nil Few epi.cells
Before 9800 57 36 7 50 38 108 138 Nil Nil Few epi.cells
After 9600 62 34 4 12 15 128 143 Nil Nil Few epi.cells
Before 9800 60 36 4 4 9 170 160 Nil + Occ.puscells
After 9200 62 34 4 4 8 162 181 Nil + Few epi.cells
Before 9500 59 36 5 18 26 112 142 Nil Nil Occ.puscells
After 9200 54 41 5 7 16 120 128 Nil Nil Few epi.cells
Before 9700 56 39 5 5 9 123 136 Nil Nil Few epi.cells
After 9600 56 41 3 4 9 112 128 Nil Nil Few epi.cells
21/04/07 12/06/07
S.
No
Sex Occupation
 Date Date
Duration
1 4133 Saroja 47
Blood
DC - % ESR - mmComplaints Stage
Sneezing, nasal congestion, 
head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, nasal congestion, 
head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose,  
head ache
Sneezing, nasal congestion, 
head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
head ache
OP.
No
Name Age
Rt. frontal sinusitis
Alb Sug
Sneezing, running nose, 
nasal congestion, head ache
Urine
F H.wife Good
Dep PNS
Results
2
3
4966
Satheesh 
Kumar
Vimal5161
43 M Shop Worker 23/04/07 28/05/07 Bi.lat frontal sinusitis Good
GoodRt. maxillary sinusitis30/05/07
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, nasal congestion, 
head ache
24/04/07Press workerM25
4 8021 Arumugam 43 M Vendor 02/05/07 05/06/07
Bi.lat maxillary 
sinusitis
Good
GoodNormal study17/06/0712/05/07I T workerM24Anand79445
6 9472 Natarajan 53 M Koolie 04/06/07 09/07/07 Rt.frontal sinusitis Good
Moderate
Bi.lat maxillary 
sinusitis
10/07/0707/06/07H.wifeF52Shanthi4157
8 4330  Ekambaram                           65 M Koolie 19/06/07 27/07/07
Bi lat.maxillary 
sinusitis
Good
Moderate
Bi lat.maxillary 
sinusitis
03/08/0719/06/07H.wifeF33Amutha4342
6220 Latha 35 F H.wife 20/06/07 03/08/07
Bi lat.maxillary 
sinusitis
Good
Good
Bi lat.maxillary 
sinusitis
01/07/8725/06/07H.wifeF30Hema627211
12 6278 Geetha 37 F H.wife 25/06/07 01/07/87
Bi lat.maxillary 
sinusitis
Moderate
GoodBi.lat frontal sinusitis01/07/8729/06/07KoolieM50Hyder Ali745213
14 9116 Selvi 40 F H.wife 03/07/07 10/08/07
Bi lat maxillary 
sinusitis
Moderate
Moderate
Bi lat max & frontal 
sinusitis
10/08/0711/07/07H.wifeF29 Tharani15 1938
10
9
X-ray
TC Sug - R Chl
cells/cu.mm P L E 1/2hr 1hr mg/dl mg/dl
S.
No
Sex Occupation
 Date Date
Duration Blood
DC - % ESR - mmComplaints Stage
OP.
No
Name Age
Alb Sug
Urine
Dep PNS
Results
Before 9800 60 34 6 14 30 118 214 Nil Nil Few epi.cells
After 9600 58 38 4 12 18 112 196 Nil Nil Few epi.cells
Before 9800 56 40 4 12 25 123 162 Nil Nil Few epi.cells
After 9600 52 46 2 8 15 123 156 Nil Nil Few epi.cells
Before 9400 52 43 5 4 12 99 175 Nil Nil Occ.puscells
After 9400 58 37 5 2 10 102 168 Nil Nil Few epi.cells
Before 9400 52 44 4 25 54 110 146 Nil Nil Few epi.cells
After 8600 58 38 4 12 17 112 132 Nil Nil Few epi.cells
Before 9800 56 35 7 15 32 118 177 Nil Nil Few epi.cells
After 9400 58 39 5 11 15 113 158 Nil Nil Few epi.cells
Before 10800 64 31 5 10 18 92 123 Nil Nil Few epi.cells
After 9600 62 34 4 6 13 108 138 Nil Nil Few epi.cells
Before 10200 60 32 8 12 25 120 163 Nil Nil Few epi.cells
After 8600 54 40 6 9 16 116 148 Nil Nil Few epi.cells
Before 9800 59 36 5 4 9 119 142 Nil Nil Occ.puscells
After 9400 64 32 4 3 9 122 153 Nil Nil Few epi.cells
Before 9900 63 31 6 12 25 138 173 Nil Nil Few epi.cells
After 9600 60 36 4 10 14 118 179 Nil Nil Few epi.cells
Before 10200 64 31 5 12 20 138 180 Nil Nil Few epi.cells
After 9800 56 40 4 8 16 136 176 Nil Nil Few epi.cells
Before 9400 55 42 5 12 20 102 128 Nil Nil Few epi.cells
After 9600 58 38 4 10 15 98 132 Nil Nil Few epi.cells
Before 9300 54 40 6 8 20 112 153 Nil Nil Few epi.cells
After 8200 56 39 5 4 12 122 148 Nil Nil Few epi.cells
Before 10200 62 31 7 12 25 138 163 Nil + Few epi.cells
After 9800 54 42 4 12 15 126 159 Nil + Few epi.cells
Before 10200 62 30 8 12 25 125 169 Nil Nil Few epi.cells
After 9400 58 36 6 10 16 118 166 Nil Nil Few epi.cells
Before 9800 60 32 8 2 5 114 135 Nil Nil Few epi.cells
After 9400 58 37 5 2 6 102 132 Nil Nil Few epi.cells
Sneezing,running 
nose,headache
Sneezing, running nose, 
nasal congestion
Running nose, nasal 
congestion, head ache
Sneezing, running nose, 
head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
nasal congestion
Sneezing, running nose, 
nasal congestion
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
nasal congestion
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
head ache
16 2336 Panchavarnam 42 F H.wife 12/07/07 17/08/07 Lt maxillary sinusitis Moderate
GoodLt maxillary sinusitis17 6771  Anitha 26 F H.wife 24/07/07 26/08/07
25 7682 Shanthi 40 F H.wife 19/11/07 07/01/08
24 8674 Chockammal 47 F H.wife 16/11/07 21/12/07
18 9490 Yasotha 40 F H.wife 18/10/07 13/11/07
13/12/0718/10/07StenoF30Thenmozhi95419
20 383 Kabila 40 F H.wife 22/10/07 11/01/08
10/12/0814/11/07Sales managerM42Veeramani697623
21 6783 Suresh 18 M Student 12/11/07 20/12/07
22 6162 Sulochana 45 F H.wife 12/11/07 31/12/07
26 2313 Kalaivani 18 F Student 29/11/07 11/01/08
27 4512 Dhanalakshmi 27 F H.wife 05/12/07 17/01/08
28 4554 Basheera Banu 33 F H.wife 05/12/07 23/01/08
30 5124 Gunaseelan 30 M Press worker 07/12/07 23/01/08
29 4848 Kalaivani 38 F H.wife 06/12/07 23/01/08
Bi lat maxillary 
sinusitis
Moderate
Bi lat maxillary 
sinusitis
Moderate
Bi lat maxillary 
sinusitis
Moderate
Rt.max & frontal 
sinusitis
Good
Bi lat maxillary 
sinusitis
Moderate
Normal study Good
Bi lat maxillary 
sinusitis
Good
Rt maxillary sinusitis Good
Bi lat max & frontal 
sinusitis
Moderate
Normal study Good
Bi lat max & frontal 
sinusitis
Moderate
Normal study Good
Bi lat maxillary 
sinusitis
Moderate
X-ray
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cells/cu.mm P L E 1/2hr 1hr mg/dl mg/dl
S.
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No
Name Age
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Urine
Dep PNS
Results
Before 9000 50 45 5 11 20 128 137 Nil Nil Few epi.cells
After 9200 53 42 5 7 14 116 140 Nil Nil Few epi.cells
Before 9400 63 35 2 10 18 92 128 Nil Nil Few epi.cells
After 9400 52 46 2 10 12 100 138 Nil Nil Few epi.cells
Before 9500 57 36 7 12 20 83 182 Nil Nil Few epi.cells
After 9200 62 34 4 7 14 96 158 Nil Nil Few epi.cells
Before 9200 54 42 4 2 3 102 172 Nil Nil Few epi.cells
After 9200 54 40 4 2 3 98 166 Nil Nil Few epi.cells
Before 9800 57 38 5 5 12 133 188 Nil Nil Occ.puscells
After 9200 54 41 5 5 11 128 162 Nil Nil Few epi.cells
Before 9400 56 36 8 10 21 120 175 Nil Nil Few epi.cells
After 9600 58 36 6 9 15 115 165 Nil Nil Few epi.cells
Before 9400 57 36 7 11 20 82 149 Nil Nil Few epi.cells
After 9600 60 34 6 7 16 95 142 Nil Nil Few epi.cells
Before 10400 60 26 # 12 20 115 167 Nil Nil Occ.puscells
After 9800 62 29 9 11 18 112 160 Nil Nil Few epi.cells
Before 9000 53 42 5 12 20 130 186 Nil Nil Few epi.cells
After 9000 58 38 4 10 18 122 170 Nil Nil Few epi.cells
Before 9300 52 42 6 15 36 115 180 Nil Nil Few epi.cells
After 9400 56 39 5 12 20 110 182 Nil Nil Few epi.cells
Before 9800 59 35 6 16 22 87 191 Nil Nil Occ.puscells
After 9600 54 42 4 10 14 92 180 Nil Nil Few epi.cells
Before 10200 60 34 6 5 11 89 146 Nil Nil Few epi.cells
After 9800 58 37 5 7 10 96 152 Nil Nil Few epi.cells
Before 9800 59 35 6 16 22 168 169 Nil Nil Occ.puscells
After 9200 64 30 6 10 17 155 140 Nil Nil Few epi.cells
Before 9200 55 41 4 11 20 99 177 Nil Nil Few epi.cells
After 9400 65 31 4 8 12 112 172 Nil Nil Few epi.cells
TC Total WBC Count Sug  - R Sugar Random
DC Differential Count Chl Cholestrol
P Polymorphs Alb Albumin
L Leucocytes Dep Deposits
E Eosinophils PNS Para Nasal Sinuses
ESR Ertthrocyte Sedimentation Rate
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Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
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Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, nasal congestion, 
head ache
Sneezing, running nose,  
head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, running nose, 
nasal congestion, head ache
Sneezing, nasal congestion, 
head ache
Sneezing, nasal congestion, 
head ache
31 5204 Durgadarshini 22 F Student 07/12/07 23/01/08
32 2025 Saraswathi 20 F Tailor 10/12/07 26/01/08
33 6191 Mumtaz 35 F Steno 10/12/07 23/01/08
34 6043 Selvaraj 27 M Electrician 10/12/07 28/01/08
35 6304 Beula 37 F H.wife 10/12/07 28/01/08
37 6987 Ramani 23 M Student 12/12/07 28/01/08
38 7104 Jayashree 32 H.wifeF 12/12/07 28/01/08
39 7520 Jesintha 39 F Servant 13/12/07 31/01/08
40 7411 Lalitha 49 F H.wife 13/12/07 31/01/08
36 7438 Padmavathi 40 F H.wife 10/12/07 01/02/08
41 7412 Vimala 43 F H.wife 13/12/07 04/02/08
42 5095 Arasu 35 M Peon 17/12/07 01/02/08
43 8826
Karunamoorth
y
52 M Koolie 17/12/07 03/02/08
44 9031 Shanthi 40 F H.wife 17/12/07 05/02/08
Bi lat maxillary 
sinusitis
Good
Bi lat max & frontal 
sinusitis
Poor
Rt maxillary sinusitis Good
Bi lat maxillary 
sinusitis
Moderate
Normal study Good
Rt maxillary sinusitis Moderate
Bi lat maxillary 
sinusitis
Good
Bi lat maxillary 
sinusitis
Good
Bi lat maxillary 
sinusitis
Poor
Bi lat maxillary 
sinusitis
Good
Bi lat maxillary 
sinusitis
Moderate
Bi lat maxillary 
sinusitis
Good
Bi lat maxillary 
sinusitis
Moderate
Bi lat maxillary 
sinusitis
Poor
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Clinical Assessment: 
The clinical study was subjected to 50 selected cases. 6 patients with drew 
from the treatment. The following parameters were observed during the course of 
treatement. 
 Age 
 Sex 
 Socio – economic status 
 Occupational status 
 Clinical features 
Age:  
Amongst 44 patients, 3 belonged to less than 20 years group, 11 were from 21 
to 31 years group, 16 were from 31 to 40 years , 10 in 41 to 50 years, 3 in 51 to 60 and 
1 above 60. The percentage population is as follows: 
  
Agewise Population
0%
10%
20%
30%
40%
% Population 7% 25% 36% 23% 7% 2%
<20 21 to 30 31 to 40 41 to 50 51 to 60 > 60
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Sex: 
Amongst 44 patients, 14 patients were males and 30 were females. The 
percentage ratio is as follows: 
Male - Female Ratio
0%
20%
40%
60%
80%
% Population 32% 68%
Male Female
Socio Economic Status: 
Amongst 44 patients, 25 patients were poor, 18 in Lower middle class and 1 in 
upper middle class. There were none in rich class. The percentage in the above 
classification is as follows. 
Occupational  Status
0%
10%
20%
30%
40%
50%
60%
% Population 11% 55% 9% 23% 2%
Employed House Wife Student Unorganise Small 
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Personal Habits and diet: 
Out of 44 patients 10 were vegetarians and 34 were mixed. 2 were smokers and 
1 alcoholic. The percentage composition is as follows: 
Personal habits
0%
50%
100%
% Population 23% 77% 5% 2%
Vegetarian Mixed Smokers Alchoholic
Occupational Status: 
Out of 44 patients, 5 were employed in regular employment, 24 were house 
wives, 4 were students, 10 engaged in unorganized sector, and 1 was a small vendor. 
The percentage composition is as follows: 
Economic Status
0%
10%
20%
30%
40%
50%
60%
% Population 57% 41% 2%
Poor Lower Middle Upper Middle
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Improvement in Sneezing: 
The no. of patients reported severe sneezing were 30 before treatment and it 
was nil after treatment. The moderate cases were 6 before treatment and 5 after 
treatment. The mild cases which were 7 became 27 after treatment and the nil cases 
rose from 1 before treatment to 12 after treatment. The results are as follows: 
Sneezing - No of Cases in different Intensity Levels
0
10
20
30
40
Intensity Levels
N
o
 o
f 
c
a
s
e
s
Before 30 6 7 1
After 0 5 27 12
Severe (3) Moderate (2) Mild (1) Nil (0)
Descriptive Statistics for Sneezing 
Sneezing Before vs. after treatment 
After treatment   
0 1 2 
Total 
0 1 (100) 0 0 1 
1 6 (85.7) 1 (14.3) 0 7 
2 1 (16.7) 5 (83.3) 0 6 
Before 
treatment  
3 4 (13.3) 21 (70) 5 (16.7) 30 
 Total 12 27 5 44 
Chi – square test table 
 Chi-square P – value 
Pearson chi square 19.40 0.004 
From the above table we got a significant difference (p< 0.05), so we conclude 
that there is an improvement between before and after treatment. 
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4 patients had good improvement, while 22 patients had moderate 
improvement. 16 had mild improvement and 2 reported no improvement. The % 
improvement is shown below. 
Sneezing Improvement
0%
10%
20%
30%
40%
50%
60%
 % Improvement 9% 50% 36% 5%
Good Improvement Moderate Mild Improvement No Improvement (0)
Improvement in Rhinitis: 
The no. of patients reported severe rhinitis was 25 before treatment and it was 
nil after treatment. The moderate cases were 2 before treatment and 5 after treatment. 
The mild cases which were 14 became 24 after treatment and the nil cases rose from 3 
before treatment to 15 after treatment. The results are as follows: 
Rhinitis  - No. of Cases in different Intensity Levels
0
10
20
30
Intensity Levels
N
o
 o
f 
c
a
s
e
s
Before 25 2 14 3
After 0 5 24 15
Severe (3) Moderate (2) Mild (1) Nil (0)
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Descriptive Statistics for Rhinitis 
Rhinitis Before vs. after treatment 
After treatment   
0 1 2 
Total 
0 3 (100) 0 0 3 
1 10 (71.4) 3 (21.4) 1 (7.1) 14 
2 1 (50) 1 (50) 0 2 
Before 
treatment  
3 1 (4) 20 (80) 4 (16) 25 
 Total 15 24 5 44 
Chi – square test table 
 Chi-square P – value 
Pearson chi square 25.03 0.000 
From the above table we got a significant difference (p< 0.05), so we conclude 
that there is an improvement between before and after treatment. 
1 patient had good improvement, while 21 patients had moderate 
improvement. 15 had mild improvement and 7 reported no improvement. The % 
improvement is shown below. 
Rhinitis Improvement
0%
10%
20%
30%
40%
50%
60%
% Improvement 2% 48% 34% 16%
Good Improvement Moderate Mild Improvement No Improvement 
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Improvement in Nasal Congestion: 
The no. of patients reported severe nasal congestion was 25 before treatment 
and it was nil after treatment. The moderate cases were 11 before treatment and 6 after 
treatment. The mild cases which were 3 became 29 after treatment and the nil cases 
rose from 5 before treatment to 9 after treatment. The results are as follows: 
Nasal Congestion - Cases in different Intensity Level
0
10
20
30
40
Intensity
N
o
. 
o
f 
c
a
s
e
s
Before 25 11 3 5
After 0 6 29 9
Severe (3) Moderate (2) Mild (1) Nil (0)
Descriptive Statistics for Nasal Congestion   
Nasal Congestion Before vs. after treatment 
After treatment   
0 1 2 
Total 
0 5 (100) 0 0 5 
1 1 (33.3) 2 (66.7) 0 3 
2 2 (18.2) 9 (81.8) 0 11 
Before 
treatment  
3 1 (4.0) 18 (72.0) 6 (24.0) 25 
 Total 9 29 6 44 
Chi – square test table 
 Chi-square P – value 
Pearson chi square 27.47 0.004 
From the above table we got a significant difference (p< 0.05), so we conclude 
that there is an improvement between before and after treatment. 
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1 patient had good improvement, while 20 patients had moderate 
improvement. 16 had mild improvement and 7 reported no improvement. The % 
improvement is shown below. 
Improvement in Headache: 
The no. of patients reported severe headache were 24 before treatment and it 
was nil after treatment. The moderate cases were 13 before treatment and nil after 
treatment. The mild cases which were 5 became 12 after treatment and the nil cases 
rose from 2 before treatment to 32 after treatment. The results are as follows: 
Headache - No. of Cases in different VA Scale
0
20
40
VA Scale
N
o
 o
f 
c
a
s
e
s
Before 2 5 13 24
After 32 12 0 0
No pain mild pain moderate (interferes moderate (interferes
0 1 - 3 3 - 5 5 - 7
Nasal Congestion Improvement
0%
10%
20%
30%
40%
50%
% Improvement 2% 45% 36% 16%
Good Improvement Moderate Mild Improvement No Improvement 
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Descriptive Statistics for Headache 
 Mean Standard Deviation Standard Error of Mean 
Pain before treatment 
Pain after treatment 
4.57 
0.30 
1.92 
0.51 
0.29 
0.08 
From the table we have arrived at the descriptive statistics like Mean, S.D., and 
S.E. of Mean for the pain score before and after treatment. 
T-Table 
 Mean Standard 
Dev. 
S.E t-value p-value 
Pre vs. Post 4.27 1.92 0.29 14.75 0.000 
From the above table we have arrived a highly significant difference (p< 0.05) 
so we conclude that there is an improvement between before and after treatment. 
24 patients had good improvement, while 12 patients had moderate 
improvement. 5 had mild improvement and 3 reported no improvement. The % 
improvement is shown below. 
 Improvement % in Headache
0%
20%
40%
60%
Level of Improvement
%
 o
f 
c
a
s
e
s
% Improvement 55% 27% 11% 7%
High level of Moderate Mild improvement No improvement
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5. Discussion 
According to ‘Kannusamy Pillai Parmbarai Vaidhyam’, ‘Karpoora 
mezhugu’ indicated for ‘Peenisam’. The prevalence of ‘Peenisam’has increased in 
the last decade due to increased pollution, urban sprawl and increased drug resistance 
caused by frequent consumption of antibiotics. 
 ‘Karpoora mezhugu’ is not widely prescribed for ‘Peenisam’, though it 
is easy to prepare and cost effective. Hence, it was decided to study the impact of 
‘Karpoora mezhugu, pharmacologically and clinically. 
The review of literature confirmed that, individually the ingredients in 
Karpoora mezhugu’ have action on ‘Peenisam” 
 Camphor and Valmizhagu have antiseptic property 
 Camphor is known to be used in the irritable conditions of the nasal 
mucus membrane. 
 Mathuzhai verpattai exerts antibiotic and immunomodulatory
activities 
 Valmizhagu and Kirambu posses anti-oxidant properties 
 Methyl - Salicylate present in Kirambu acts as a pain killer 
 Previous studies revealed that Jaggery acts as a protective agent for 
workers in dusty and smoky environment. 
 Vitamin C present in Lime Juice and Jaggery builds body resistance 
against infections 31 and the anti inflammatory 3 property of vitamin 
‘C’ helps to reduce inflammation  of nasal mucosa. 
Bio-chemical analysis showed the presence of Sulphate, Chloride, Oxalate, 
Aluminium, Calcium and Magnesium. 
Preliminary phyto chemical analysis revealed the presence of sugar, tannins, 
flavonoids, triterpenoids and steroids. 
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Flavonoids have shown antibacterial and anti-inflammatory activity. 28
Terpenoids exert antiseptic, analgesic and stimulant properties. 28
Tannins posses mild antiseptic action. 28
Antimicrobial study shows that ‘Karpoora mezhugu’ have excellent activity 
against Straphylococcus aureus.. Moderate activity against Pseudomonas
auerginosa which is useful in treating ‘Peenisam’. 
Pharmacological studies showed that acute toxicity of the drug is 4000 
mg/Kg. in animal models. 
The anti-inflammatory activity was statistically significant (P<0.05) at the 
concentration of 400 mg/Kg.  
In the doses of 400 and 800 mg/Kg body weight ‘Karpoora mezhugu’ shows 
significant analgesic activity. 
In anti-histaminic study, as low as 1mg/ml of the drug produced inhibition on 
isolated guinea pig ileum is significant 
For clinical study 50 patients were selected between the age group of 16 to 65 
years. Out of these 6 patients discontinued the treatment on various withdrawal 
criteria . ‘Karpoora mezhugu’ was administered at the dose of 400 mg twice daily 
with water. Amongst 44 patients, 
 9% had good improvement in sneezing, 50% moderate, 36% mild and 5% no 
improvement 
 2% had good improvement in rhinitis, 48 % moderate, 36% mild and 16% no 
improvement 
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 2% had good improvement in nasal congestion, 45 % moderate, 36% mild and 
16% no improvement 
 55%  had good improvement in head-ache, 27 % moderate, 11% mild and 7% 
no improvement 
Clinically there were no significant adverse effects reported or observed during 
the entire study period. 
Except “Salt” taste, Karpoora Mezhugu has the other 5 tastes. 
 “Karpu, kaipu and thuvarpu tastes are helpful in alleviating ‘Kapha”, 
which is the main cause for Peenisam. 
‘Peenisam’ also occurs in ‘Pitha Kapha’ and ‘Kapha Vatha’, ‘Nadi 
combinations’. ‘Sweet’ taste neutralizes ‘Pitha’ and the ‘Sour’ taste neutralizes 
‘Vatha’. 
Karpooram, Kirambu and Valmizhagu have ‘Veppa Veerium’ and 
‘Stimulant’ action, which are useful in the treatment of ‘Peenisam’. 
‘Thatpa Veerium’ of Mathuzhai Ver Pattai and ‘Seetha Veerium’ of Lime 
juice and Vellam, do not allow to exceed the ‘Vepa Veerium’ of the above drugs 
beyond the normal limits.  The astringent  property of Mathuzhai Verpattai prevents 
the gastric disturbances that arise from the above ‘Vepa Veria’ substances 
Karpooram is alkaline (Uppu Sarakku) and Lime juice is acidic (Pulli Sarakku) 
in nature. By heating Karpooram with lime juice, the toxicity of karpooram was 
removed.30
From the above studies and discussion it is evident that Karpoora mezhugu is  
effective in the treatment of  Peenisam. 
Part - 2 
A Study on Karpoora Mezhugu for Peenisam 
Summary and Conclusion 
107
6. Summary and Conclusion 
‘Karpoora Mezhugu’ is one of the effective drug which is cost effective and 
easy to prepare. Hence it has been selected and various studies were carried out to find 
its efficacy in treating Peenisam. 
 The acute toxicity of the drug is 400 mg/kg, in animal models. 
 Pharmacological study shows, that it has mild anti-inflammatory, good 
analgesic and excellent anti-histaminic activities.
 Clinical study shows, statistically significant improvement in sneezing, 
running nose, nasal congestion, and headache. 
 The percentage improvement in the slab – ‘moderate improvement’ is 
high in sneezing (50%), rhinitis (48%) and nasal congestion (45%). For 
headache, the percentage improvement in the slab - “good 
improvement” is high (55%). 
Even with 6 weeks of treatment, ‘Karpoora Mezhugu’ has shown moderate to high 
improvement in all the symptoms of Peenisam. Hence further studies can be made to 
assess its efficacy in long term treatment. 
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